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Quantification of highly homologous human liver drug-metabolizing enzymes (DMEs) has been 
a challenging task in drug metabolism and disposition research, due to a lack of specific 
antibodies and marker substrates. Mass spectrometry (MS) techniques and applications have 
evolved significantly, striving to achieve absolute and specific quantification of these enzymes. 
Since the first absolute quantification of cytochrome P450s (CYPs) using the attachment of 
isotope tags to free thiols (iCAT), MS-based quantification has become much more versatile, 
cheaper, and easier to use. Today, variations of liquid chromatography-multiple reaction 
monitoring (LC-MRM)-based targeted proteomics, such as AQUA (absolute quantification) and 
QconCAT (concatenated signature peptides), have become the gold standards for quantification. 
These new methods have driven the absolute quantification of DMEs to become a routine 
laboratory task. 
Many drug metabolism-related projects require absolute enzyme quantification. For example, 
precise knowledge of enzyme expression during ontogeny is a necessity to aid pharmacists in 
planning drug-dosing regimens for patients of different age groups. Additional examples include 
the need for accurate cellular enzyme expression profiles when establishing new drug-screening 
cell models and when elucidating molecular mechanisms underlying hypothesized drug-drug 
interactions. This dissertation demonstrates how an LC-MRM targeted approach contributes to 
these three areas. First, an ultra-performance liquid chromatography (UPLC)-MRM targeted 
quantification method was developed and validated, focusing specifically on the quantification of 
CYP2C and flavin-containing monoxoygenase (FMO) isoforms. Second, the newly developed, 
as well as existing, UPLC-MRM quantification methods were used to confirm previously 
reported DME ontogeny patterns and establish patterns for CYP4F and FMO5. Third, targeted 
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proteomic quantification was employed for the absolute quantification of CYPs 1A1, 1A2 and 
1B1 in KLE cells and different human tissue microsomes to aid the establishment of CYP1B1-
dependent cell models for the screening of anticancer prodrugs. Lastly, CYP4F2-specific 
targeted quantification was used to confirm the mechanism underlying a potential drug-drug 
interaction between warfarin and lovastatin.  
UPLC-MRM-based targeted proteomic techniques have many advantages, but the cost and time 
required for method development rises linearly with an increase in the number of targeted 
proteins. An emerging technique utilizing label-free data independent analysis (DIA) with high-
resolution mass spectrometry (HDMS) offers the global quantification of hundreds of proteins at 
a negligible cost; however, there are numerous hurdles when using this technique. We introduced 
a new sample processing method, quantitative filter-assisted sample preparation (qFASP), which 
allows full recovery and analysis of clean, digested proteomic peptides. With qFASP and 
additional optimized procedures, many of the hurdles encountered with DIA quantification were 
mitigated. Very strong quantitative correlations were observed between the new DIA/ HDMS 
technique and the well-established targeted proteomics for DME quantification.  
In summary, this dissertation describes a targeted and an untargeted (DIA) quantitative 
proteomic method for the multiplexed absolute quantification of human hepatic DMEs and their 
applications to developmental pharmacology. Quantification coherence achieved between the 
targeted and the untargeted proteomic methods was made possible by a newly developed qFASP 
sample preparation protocol, which allowed quantitative and reproducible recovery of peptides 
after filter-assisted sample cleanup and protein digestion. These methods are expected to enrich 
our knowledge regarding ontogenetic changes of human DMEs and establish necessary 
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1.1 Overall Goal of Dissertation  
Human hepatic DMEs play a critically important role in drug metabolism. Advances in the 
pharmaceutical industry combined with new drug discovery require more effort in the discovery 
and research of DMEs and their impact in the field. Mass spectrometry-based DME 
measurements bring unprecedented accuracy, simplicity, and multiplexing to drug metabolism 
and disposition research. This dissertation details the development of methods to quantify DMEs 
using MS-based targeted proteomics and how targeted proteomics can be applied to research 
focused on age-dependent DME expression, the establishment of cell models for CYP dependent 
anticancer prodrug screening, and investigation of potential drug-drug interactions. Finally, 
attempts are made to solve the problems of label-free DIA quantification and apply the use of 
this technique to quantitative DME analysis.  
 
1.2 Significance and Nomenclature of Human Liver CYPs and FMOs  
Cytochrome P450s (CYPs) are a superfamily of oxidoreductases that catalyze the oxidation of 
food, pharmaceuticals, environmental chemicals, and endogenous substances. CYPs exist in 
almost all living organisms, including animals, plants, bacteria, fungi, archaea and viruses (1). 
Over 350 families and 3000 unique sequences encoding this class of enzymes have been 
discovered, and these numbers continue to grow (2). CYPs are of critical importance to the 
pharmaceutical industry as they are responsible for the phase I metabolism of a majority of 
clinically used small molecule pharmaceuticals (3). CYPs not only metabolize and detoxify 
drugs, they also catalytically activate pro-toxins and pro-carcinogens. The capability of CYPs to 
activate toxins has been used against cancers; some chemotherapy drugs, such as ifosfamide, 
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cyclophosphamide and dacarbazine, are specifically activated in tumor tissues (4). CYPs are 
known to mediate drug-drug interactions. Patients taking amiodarone or metronidazole have an 
increased risk of bleeding if they also are on warfarin, as amiodarone and metronidazole are 
inhibitors of the warfarin-metabolizing enzymes CYP3A4 and/or CYP2C9 (5). CYP expression 
levels change drastically at different human developmental stages, which can affect drug 
clearance. For example, both diazepam and theophyline have low clearance rates in neonates, 
newborns and seniors, while adults have higher clearance rates. These differences can impact 
greatly the design of new drug dosing regimens for people of different age groups (6). 
Fifty-seven CYP genes have been identified in humans. A nomenclature system helps to identify 
each individual isoform. All enzymes share the superfamily root symbol “CYP”. The first 
number that follows CYP (e.g., CYP1, CYP2 and CYP3) codes for the family. Enzymes falling 
into the same family share over 40% amino acid sequence identity. The letter that follows (e.g., 
CYP1A and CYP1B) identifies the subfamily, in which enzymes share greater than 55% amino 
acid identity. The final number (e.g., CYP3A4, CYP3A5 and CYP3A7) indicates the individual 
isoform (7). Many CYP enzymes are highly homologous; for example, CYP3A4 and CYP3A5 
share 87% sequence identity and CYP4F2 and CYP4F3B share 93% sequence identity (8).  
Flavin-containing monooxygenases (FMOs; EC 1.14.13.8) are flavin adenine dinucleotide 
(FAD)- and Nicotinamide adenine dinucleotide phosphate (NADPH)-dependent microsomal 
enzymes that have a significant role in the metabolism and detoxification of pharmaceuticals, 
endogenous substances and environmental compounds. FMOs catalyze the oxygenation of soft 
nucleophilic heteroatom-containing (e.g., N, S and P) organic substances, converting them to 
more readily excreted polar metabolites. Five functional human FMO isozymes (FMO1- FMO5) 
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have been discovered; among these, FMOs 1, 3 and 5 are relevant to hepatic drug metabolism (9-
11). 
Human liver has the most CYPs and FMOs expressed; expression of these enzymes dictates drug 
pharmacokinetics, toxicity, and efficacy (12). Thus, quantification of these hepatic enzymes is 
practiced regularly in pharmaceutical research and development.  
1.3 Basic Principles and Advantages of Mass Spectrometry-Based Quantification of Drug-
Metabolizing Enzymes 
Drug-metabolizing enzyme (DME) expression has been quantified traditionally using immuno-
blotting based techniques such as an ELISA (enzyme-linked immunosorbent assay) or Western 
blot. These techniques are sensitive, versatile, and easy to use; however, they suffer from limited 
dynamic range, limited multiplexing, or lack specificity to differentiate highly homologous DME 
isozymes (8). Mass spectrometry (MS)-based proteomic quantification was developed to answer 
these challenges. Fundamentally, protein mixtures are digested by endo-proteases, yielding 
predictable sequences of peptides. All peptides are subjected to liquid chromatography (LC) 
separation and MS analysis. The peptides with sequences that are unique to the protein of interest 
are called signature peptides. Each signature peptide has a specific chromatographic retention 
time (RT) and mass-to-charge ratio (m/z) which are measured by (U)HPLC and MS, 
respectively. By measuring how much signature peptides are present, the concentrations of the 
corresponding protein can be extrapolated using known concentrations of (calibration) standards 
(Figure 1). This signature peptide-based protein quantification has been proven to provide a large 
linear quantification range, great level of multiplexing, and excellent selectivity. In addition, 
synthesizing signature peptides is far easier and cheaper than the production of new specific 
antibodies. Thus, the development of MS-based assays for protein quantification is cheaper and 
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faster than that of immuno-blotting-based techniques.  
 
Figure 1. Illustration of basic principle of signature peptide-based MS protein quantification. 
Presently, the quantification of DMEs is much more simplified and well developed than in the 
past. However, the simplicity and sophistication of such techniques was not achieved in a day. 
The sections following discuss very brief histories of the evolution of MS-based absolute 
quantification of DMEs.  
1.4 The First Mass Spectrometry-Based Absolute Quantification of CYPs in Mice Through 
ICAT® Labeling 
The first absolute quantification of CYP enzymes by MS was published in 2006 by Jenkins et. al. 
(13). At that time, quantification of relative protein expression via MS was enabled by isotope 
tagging. Control and experimental samples were labeled with light (12C, 14N or 1H) and heavy 
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(13C, 15N or 2H) isotope tags, respectively. The light and heavy tagged proteins then were mixed 
together, digested, and analyzed by LC-MS/MS. Signature peptides from control and 
experimental samples were differentiated by mass; they have similar chemical properties that 
result in the same retention time on LC columns and signal response in mass spectrometer. 
Comparison of the labeled peptides revealed relative protein abundance (14). Jenkins et. al. used 
the isotope coded affinity tag (iCAT) technique, in which the tag was incorporated with heavy 2H 
or light 1H and was conjugated to free cysteines in peptides. The tag also was linked to biotin, 
which has a high affinity for avidin, so that avidin affinity chromatography selectively pulled out 
tagged peptides. The biotin linker then was cleaved, freeing captured signature peptides for MS 
analysis. iCAT allowed Jenkins et. al. to do proteomic profiling of DMEs in mouse liver 
microsomes. The control and experimental samples and synthetic signature peptides were all 
labeled with heavy iCAT tags. The MS response of the signature peptides in the control and 
experimental samples were calibrated using known concentrations of synthetic peptides. The 
absolute quantities of eight mouse CYP proteins were measured for the first time by MS.  
Despite the successful first leap in MS-based absolute CYP quantification, the limitation of the 
method was quite obvious. The iCAT technique only labels free thiol groups. If CYP isozymes 
can be differentiated only by cysteine-lacking signature peptides, they will not be able to be 
quantified specifically by such a technique.  
1.5 Other Peptide Labeling Techniques That Attempted to Overcome iCAT Limitations  
To overcome the limitation of iCAT to solely label free thiol-containing peptides, C.S. Lane et. 
al., in 2007, attempted to label CYP peptides with 18O (2). Equal amounts of microsomes from 
normal and chemical-treated mice were separated on a PAGE gel. Protein bands were excised 
and subjected to in-gel tryptic digestion. Tryptic peptides from treated animals were incubated 
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with H2
18O-containing trypsin, while those from control animals were dissolved in H2
16O-
containing trypsin. Trypsin is able to incorporate 18O or 16O into peptides. The resulting peptides 
were combined and analyzed by LC-MS/MS. Peptides incorporating 18O or 16O were co-eluted 
during LC and could be differentiated only by their mass. Relative CYP expressions were 
measured by comparing peak areas of signature peptides that had been labeled with 18O or 16O. 
Using the 18O/16O labeling technique, C.S. Lane et. al. were able to identify 9 CYPs that were 
up-regulated and 4 CYPs that were down regulated as a result of chemical treatment. The authors 
did admit they were unable to differentiate some of the highly homologous mouse hepatic CYP 
enzymes, such as CYP2A4/5. 
Another chemical labeling technique is iTRAQ (isotope tags for relative or absolute 
quantification). Briefly, proteins isolated from normal and treated subjects were separated on a 
gel; equivalent bands were excised. Following in-gel tryptic digestion, the iTRAQ reagent 
containing reactive groups conjugate with primary amines was added to the digests, labeling 
peptides on the N-terminal amines. The iTRAQ reagent also contains isotopes of different 
weights, allowing mixed peptides to be differentiated by MS/MS. Relative CYP expressions 
were measured in the same manner as by 16/18O labeling (14).  
Isotope chemical labeling MS quantifications are usually incredibly expensive, laborious, and 
low throughput. Simplification of these processes calls for new experimental design. 
1.6 Gel-Free Absolute Quantification of Human Liver Microsomal CYP Proteins - The 
First MS-Based Absolute Quantification of Human Liver CYPs 
A simpler solution for MS-based absolute protein quantification was published in 2003. S. A. 
Gerber et. al. quantified proteins and phospho-proteins in yeast using the AQUA (absolute 
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quantification) technique (15). Basically, stable isotope-labeled (2H, 13C or 15N) peptides that 
have the same sequences as targeted signature peptides of the proteins of interest were 
synthesized and/or chemically modified by phosphorylation, methylation, or acetylation to 
mimic the natural peptide. Proteins extracted from yeast were subjected to gel electrophoresis 
and tryptic digestion. Known concentrations of recombinant proteins were treated in the same 
manner and served as calibration standards. Resulting peptides were extracted from gel, spiked 
with stable isotope-labeled synthetic peptide counterparts and injected for LC-SRM (single 
reaction monitoring) using a tendon MS. SRM precursor and product ion transitions unique to 
the natural and synthestic peptides were selected. 
 The peak ratios between natural and stable isotope-labeled peptides from the yeast were 
compared to the ratio of recombinant calibration standards to extrapolate targeted protein 
concentrations.   
By adopting the AQUA technique, M. Z. Wang et. al. first quantified human liver microsomal 
CYP3A4, CYP3A5, and combined CYP3A (CYP3A4, CYP3A5 and CYP3A7) by LC-MRM 
(multiple reaction monitoring) with absolute quantity in 2008 (8). He further simplified the 
technique by removing in-gel digestion and replacing it with a much simpler and faster process 
involving protein reduction, denaturation, alkylation and digestion that takes place in solution. 
By avoiding in-gel digestion, Wang et. al. also were able to eliminate peptide loss during gel 
extraction, resulting in a more accurate quantification. Good assay robustness and quantification 
accuracy were demonstrated by 1) consistent quantification of two signature peptides digested 
from the same protein and 2) a strong correlation between LC-MRM measured CYP3A quantity 
and Western blot densitometry measured CYP3A quantity or specific CYP3A marker substrate 
activities. Nowadays, gel-free LC-MRM-based targeted protein quantification has been adopted 
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for the measurement of UGTs, drug transporters, and many other proteins of interest. It also is 
considered the gold standard for protein quantification (8, 12, 16-19). Quantification method 
development is far cheaper and more convenient at this stage. Another variation of AQUA 
further reduces the cost for large numbers of targeted protein quantifications.  
1.7 QconCAT, an AQUA Variant, Decreases the Cost of Large Scale Targeted Proteomic 
Quantification  
In 2005, R. J. Beynon et. al. described a method by which proteins made of concatenated 
signature peptides (QconCAT) could be constructed in E. coli that grow in isotope enriched cell 
medium after being transformed with an artificial gene in a high expression vector (20). The 
constructed protein contained at least 50 stable isotope-labeled signature peptides (50-100 kDa) 
and served as an internal standard or calibration standards for the absolute quantification of 
different targeted proteins. Compared to synthesizing the same number of stable isotope-labeled 
peptides, QconCAT is more cost-effective. Since then, QconCAT has been used for many 
applications, including the proteomic quantification of E. coli, animals, yeast and humans, and as 
a universal construct protein standard (QCAL) for the calibration of different MS platforms (21-
25).   
In 2013, M. R. Russell et. al. first applied the QconCAT approach for the quantification of 15 
CYPs and 10 5′-diphospho-glucuronosyltransferase (UGT) enzymes, with 2 signature peptides 
per targeted enzyme in the artificial protein. The initial expression of the artificial protein by the 
authors was unsuccessful until the peptide concatenation sequence was re-shuffled and the 
expression strategy changed (26).  
AQUA and QconCAT gave unprecedented versatility, ease of use, and accuracy in method 
development for LC-MRM-based protein quantification. However, cost will remain relatively 
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high as long as isotope labeling is utilized. In addition, QconCAT method development is riskier 
due to possible expression failure.  
1.8 Label-Free Data Independent Global Scale Absolute Protein Quantification with 
NanoUPLC-Q-TOF  
In 2006, Jeffrey C. Silva et. al. discovered that the intensity of the top three ionizing peptides of 
a protein is directly correlated to the protein concentration within complex biological matrices 
when the label-free data independent acquisition (DIA; MSE technique is the Waters version of 
DIA) strategy is applied to quadrupole-time of flight (Q-TOF) MS (27). The authors spiked six 
non-host recombinant proteins of known concentrations into an E. coli proteome digest and 
analyzed the results using the label-free DIA approach. The measured concentrations of the six 
spiked proteins differed from the theoretical concentrations by less than 15%. They also 
quantified well-characterized proteins in human serum and in E. coli digest; the label-free DIA 
measured values showed good correlation with historical reports.  
Label-free Q-TOF MSE-based protein quantification removes the need of isotope labeling and 
calibration standards, resulting in highly simplified method development and reduced experiment 
workload while quantifying hundreds of proteins simultaneously. Because of lower cost, greater 
multiplexing and simplicity, this technique has been adopted widely in the proteomic analysis of 
E. coli, plants, and human tissues and bodily fluids (28-32). However, due to several problematic 
factors, it has not been reported for the quantification of human liver DMEs. These factors 
include large variability in digestion and peptide loss with various protein cleanup methods (33-
35) and sample storage (36, 37), poor peptide recovery following solid phase extraction during 
sample preparation or online trap LC columns, and ill-investigated quantification inconsistency 
between label-free MSE and labeled targeted proteomics (38-40). Identifying and solving these 
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problems requires a new approach for sample preparation, which will be discussed further in 
Chapter 6.  
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Flavin-containing monooxygenases (FMOs; EC 1.14.13.8) are FAD- and NADPH-dependent 
microsomal enzymes that have a significant role in the metabolism and detoxification of 
pharmaceutical, endogenous substances and environmental compounds. FMOs catalyze the 
oxygenation of soft nucleophilic heteroatom-containing (e.g., N, S and P) organic substances, 
converting them to more readily excreted polar metabolites. Five functional human FMO 
isozymes have been discovered; among these, FMOs 1, 3 and 5 are relevant to hepatic drug 
metabolism (1-3).  
CYP2Cs are another important subfamily among human hepatic DMEs. It occupies close to one 
fifth of total human hepatic CYP expression and involved in the metabolism of 20% of small 
molecule pharmaceuticals (4, 5). There are four members in the CYP2C subfamily—CYP2C8, 
CYP2C9, CYP2C18, and CYP2C19. Among them, CYP2C9 and CYP2C19 are relatively more 
important as they are responsible for the clearance of many frequently used drugs. For example, 
CYP2C9 oxidizes tolbutamide, phenytoin, warfarin, ibuprofen, and diclofenac (6). CYP2C19 
metabolizes omeprazole, diazepam, and some barbiturates (5).   
Traditionally, FMO enzyme quantification has relied on isozyme-specific antibody-based 
immunoquantification via Western blots. For absolute quantification, FMO content has been 
determined based on FAD content, the tightly-bound prosthetic group required for the catalytic 
activity of FMO holoproteins (7). Recombinant FMOs (e.g., heterologously expressed in 
baculovirus-infected insect cells or Supersomes) have served as calibration standards (8, 9). 
Thus, previous studies have reported the quantification of FMO holoproteins, rather than total 
FMO proteins (i.e., holoprotein + apoprotein).  CYP2C9 and CYP2C19 have been quantified by 
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both Western blot and MS-based targeted proteomic approaches, but the quantification was not 
thoroughly verified by the correlation between the quantified amount and enzyme specific 
marker substrate activities (10).  
To overcome the common limitations of immunoquantification (i.e., cross-reactivity, dynamic 
range, reproducibility and multiplexity), liquid chromatography-tandem mass spectrometry (LC-
MS/MS)- and multiple reaction monitoring (MRM)-based targeted quantitative proteomic 
methods have been developed for the absolute quantification of cytochrome P450s (CYPs), 
UDP-glucuronosyltransferases (UGTs) and membrane drug transporters (4, 11-13). However, 
targeted quantitative proteomic methods for FMOs have yet to be reported. The term “absolute” 
quantification in these publications and the report herein refers to a type of proteomic 
quantification that produces protein concentration or amount, rather than “relative” protein 
expression profiles. A targeted quantitative proteomic method for absolute protein quantification 
relies on the use of either synthetic signature peptides of known concentration or signature 
peptides derived from the tryptic digest of target proteins of known concentration as calibration 
standards. The selection of appropriate signature peptides involves the in silico tryptic digestion 
of target proteins, followed by evaluation of the resulting candidate peptides based on several 
selection criteria to ensure specificity, stability and digestion efficiency (4, 14, 15). Candidate 
signature peptides (usually at least two for each protein) then can be synthesized and used to tune 
the MS (typically, a triple-quadrupole MS) for optimal MRM detection. However, some 
candidate signature peptides may not perform optimally due to poor digestion efficiency, 
chromatography or ionization during MS analysis, therefore rendering expensive signature 
peptides useless. Hence, it is desirable to incorporate an additional process(es) to verify 




The objective of the current chapter was to develop an UPLC-MRM-based targeted quantitative 
proteomic method for the absolute quantification of FMO1, FMO3 and FMO5 in human liver 
microsomes (HLM) and evaluate the quantification method by correlating quantified FMOs and 
CYP2Cs amounts to their specific substrate activities.  
2.2 Materials and Methods 
2.2.1 Chemicals, Enzymes, and Liver Tissues. Optima-grade acetonitrile, water, formic acid, 
and acetic acid were obtained from Fisher Scientific (Pittsburgh, PA). Ammonium bicarbonate, 
dimethylsulfoxide, dithiothreitol, iodoacetamide, and cimetidine were purchased from Sigma-
Aldrich (Saint Louis, MO). Cimetidine sulfoxide was acquired from Abcam Biochemicals 
(Cambridge, UK). Famotidine sulfoxide was acquired from Toronto Research Chemicals 
(Toronto, Canada). Recombinant human FMO1, FMO3, FMO5, CYP2C9, and CYP2C19 
Supersomes, prepared from baculovirus-infected insect cells expressing human FMO enzymes, 
were purchased from Corning Gentest (Woburn, MA). The FMO concentration (pmol/mL and 
pmol/mg protein) of each Supersomes, based on the FAD content determined by an HPLC-
fluorescence method or by CO difference spectrum assay (7, 16), was provided by the supplier. 
Control Supersomes (Corning Gentest) contained microsomes from insect cells infected with 
wild-type baculovirus. Synthetic unlabeled AQUA Ultimate-grade signature peptides (5 pmol/μL 
± 5% by amino acid analysis) were ordered from Thermo Scientific (Ulm, Germany). Peptide 
purity (>97%), determined by RP-HPLC UV (detection wavelength of 215 nm) and MALDI-
TOF MS, was provided by the manufacturer. Synthetic 13C and 15N stable isotope-labeled crude 
signature peptides also were acquired from Thermo Scientific. All synthetic peptide sequences 
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were confirmed by MS/MS fragmentation analysis using a Waters Xevo TQ-S triple-quadrupole 
MS (Milford, MA). Sequencing-grade modified trypsin (cat. # V5113, lot 104493) was 
purchased from Promega (Madison, WI). Pooled HLM (XTreme 200) and nine individual adult 
donor HLM (Table 1) were purchased from XenoTech, LLC (Lenexa, KS). Liver tissues from 
seven fetal (14-20 weeks gestation) donors and sixteen pediatric (aged 5 months-10 years) 
donors were obtained from the NICHD Brain and Tissue Bank for Developmental Disorders 
(Contract #HHSN275200900011C, Ref. No. NO1-HD-9-0011; Baltimore, MD) under an 




Table 1. Donor information for individual donor human liver microsomes. 
Group Sample Gender Age Race 
Adult 
H0024 Male 47 years Caucasian 
H0079a Female 56 years Caucasian 
H0081b Female 67 years Caucasian 
H0134 Female 61 years Caucasian 
H0199 Female 48 years African American 
H0232 Male 43 years Caucasian 
H0246 Female 40 years Caucasian 
H0292 Male 65 years African American 
H0307 Male 39 years Caucasian 
Fetalc 
F1 Female 18 weeks African American 
F5 Male 15 weeks African American 
F6 Female 20 weeks African American 
F7 Male 16 weeks African American 
F8 Male 15 weeks African American 
F9 Male 19 weeks Caucasian 
F10 Male 16 weeks African American 
Pediatric 
P1 Male 6 years Caucasian 
P2 Male 4 years Caucasian 
P3 Male 2 years African American 
P4 unknown 2 years unknown 
P5 unknown 1 years unknown 
P6 unknown 4 months unknown 
P7 Male 4 years Caucasian 
P8 Male 8 years Caucasian 
P9 Male 2 years African American 
P10 Female 9 years Hispanic 
P11 Female 111 days Caucasian 
P12 Female 92 days Caucasian 
P13 Male 63 days African American 
P14 Female 57 days African American 
P15 Female 97 days African American 
P16 Male 71 days African American 
a 5-6 cigarettes/day for 40 years 
b 1 pack/day for 40 years and 1 beer/month 




2.2.2 In Silico Selection of FMO, CYP2C Signature Peptides. Candidate tryptic signature 
peptides for FMO quantification were selected in silico using criteria described previously (4, 14, 
15). The selected candidate peptides for each FMO protein are listed in Table 2.  
Table 2. Candidate signature peptides identified for human FMO1, FMO3, FMO5, CYP2C9 and 
CYP2C19 based on in silico selection criteria. 
 

























CYP2C9 CYP2C9_PEP1_L GIFPLAER 98-105 903.2
CYP2C9_PEP2_L SLVDPK 460-465 656.8
CYP2C9_PEP3_L GTTILISLTSVLHDNK 384-399 1712.6
CYP2C19 CYP2C19_PEP1_L GHFPLAER 98-105 917.2


































a Start and end residue positions of peptides in the corresponding full-length protein. 




2.2.3 Trypsin Digestion. The tryptic digestion of FMO Supersomes and HLM was performed as 
described previously with minor modifications (4, 15). Briefly, protein samples (30 μg) were 
reduced in ammonium bicarbonate buffer (pH 8.0, 50 mM final concentration) containing 
dithiothreitol (4 mM final concentration) and heated at 60°C for 60 min to denature the proteins. 
After cooling to room temperature, the samples (90 μL total volume) were alkylated with 
iodoacetamide (10 mM final concentration) for 20 min in the dark prior to digestion with 1 µg 
trypsin at 37°C for 4 h unless stated otherwise. All reactions were carried out in Eppendorf 
Protein LoBind microcentrifuge tubes (Hamburg, Germany) to minimize protein and peptide loss 
due to binding. Solvent evaporation during the incubations was minimized by sealing the capped 
tubes with parafilm and applying pressure with an aluminum block. To optimize the trypsin 
digestion protocol, different digestion times (0.5, 1, 2, 4, 6, 8, 12 and 24 h) and protein-to-trypsin 
ratios (10, 20, 30, 40, 50, 60, 80 and 100:1) were examined. Reactions were cold-quenched with 
storage at -80°C. A mixture of stable isotope-labeled signature peptides (1 µL; internal 
standards) was spiked into the thawed samples prior to loading into a 6°C autosampler.  
2.2.4 Signature Peptide Verification by Post-In Silico Product Ion Screening. After 
vortexing and centrifugation (16,000 g for 10 min at 4°C), the supernatants (10 µL) of the 
quenched digestion mixtures underwent UPLC-MS/MS analysis. The UPLC-MS/MS instrument, 
consisting of a Waters Acquity UPLC I-class binary solvent manager coupled with a Waters 
Xevo TQ-S triple-quadrupole MS, was operated under positive electrospray ion mode. 
Chromatographic separation of the peptides was carried out on a reversed-phase column (Waters 
UPLC BEH-C18, 1.7 μm, 2.1 x 100 mm), fitted with an in-line column filter and a VanGuardTM 
guard-column (Waters). The mobile phases consisted of (A) water containing 0.1% (v/v) formic 
acid and (B) acetonitrile containing 0.1% (v/v) formic acid. A 13.5 min gradient (0.4 mL/min) 
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began with 2% B held for 1 min, followed by an increase to 15% B over 2 min, and to 30% B 
over the next 7 min. The column was washed with 95% B for 1.5 min and then re-equilibrated 
with 2% B for 2 min prior to the next injection.  
To detect the in silico-selected candidate signature peptides, product ion scans were set up using 
selected precursor ions corresponding to the doubly protonated ions of the candidate peptides in 
the Q1 quadrupole, fragmenting these precursor ions with a collision energy ramp (15-40 V) in 
the Q2 quadrupole, and mass analysis of the product ions in the Q3 quadrupole mass analyzer 
under a scan rate of 5000 amu/s. Extracted product ion (EPI) chromatograms of all the possible y 
ions of each candidate peptide were generated using Masslynx (Version 4.1; Waters) to allow 
visual inspection for product ion screening. A salient peak shared by most or all y ion EPI 
chromatograms verified the detection of the corresponding signature peptide. Upon detection 
verification, the signature peptide sequences were sent for synthesis (Thermo Scientific).  
2.2.5 UPLC-MRM Analysis. Lyophilized stable isotope-labeled signature peptides were 
dissolved in 1 mL of 1:1 (v/v) acetonitrile:water solution. The solution was diluted further to 
approximately 2-4 μg/mL and then infused into the Xevo TQ-S MS at 5 μL/min with an LC flow 
of 50% B at 0.4 mL/min. MRM parameters were optimized using IntelliStart (Waters) under 
positive electrospray ion mode: capillary voltage, 1.5 kV; cone voltage, 40 V; source offset, 40 
V; dissolvation temperature, 500°C; dissolvation gas, 1000 L/h; nebulizer gas, 7 bar. The 
optimum collision energy and precursor/production masses for the signature peptides are 
summarized in Table 3. UPLC-MRM quantification was performed using the peak area ratios of 
signature peptides to corresponding stable isotope-labeled signature peptides (internal standards). 
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2.2.6 Preparation of Calibration Standards. Two types of calibration standards were prepared 
for the absolute quantification of FMOs in HLM. First, recombinant FMO1, FMO3, FMO5, 
CYP2C9, and CYP2C19 Supersomes of known concentrations (based on FAD and heme 
content) were used to build calibration standards. Quality controls (QCs), consisting of FMO 
Supersomes at 0.2, 1 and 10 pmol/digestion, were prepared in triplicate. All recombinant protein 
standards and QCs were denatured, alkylated and trypsin-digested as described above, prior to 
UPLC-MRM analysis. Due to the varying amount of total proteins in the standards, additional 
trypsin (2 µg total) was used to keep the protein:trypsin ratio ≤ 30:1 in the high concentration 
standards. Second, synthetic signature peptides of known concentrations (based on amino acid 
analysis) were used to build calibration standards (0.02 to 20 pmol/digestion). To normalize total 
protein loading, control Supersomes (30 µg) were spiked into the peptide standards. The spiked 
peptide standards also were denatured, alkylated and trypsin-digested prior to UPLC-MRM 
analysis. The lower limit of quantification was defined as the lowest standard concentration with 
signal-to-noise ratio > 5 and acceptable precision and accuracy (within 20%).  
2.2.7 FMO and CYP2C Marker Substrate Activities. Cimetidine sulfoxidation is considered 
specific to the activities of FMO enzymes. The cimetidine-FMO functional activity was 
measured as described previously (17, 18). Cimetidine (1 mM; reported Km values are 4 mM for 
FMO3 and >10 mM for FMO5) was pre-incubated with HLM (0.1 mg/mL) in a phosphate buffer 
(pH 7.4, 100 mM) containing 3.3 mM MgCl2 for 5 min at 33°C. No FMO activity lost was 
detected during the 5 min of FMO cimetidine pre-incubation (data not shown). Reactions (200 
µL final volume) were initiated by the addition of 1/10 the reaction volume of NADPH solution 
(1 mM final concentration). Aliquots (10 µL each) were removed from each reaction at 1 and 5 
min and transferred to tubes containing ice-cold acetonitrile (300 µL) and famotidine sulfoxide 
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(10 nM; internal standard). Quenched reaction mixtures were centrifuged (2250 g for 20 min at 
4°C) and the resulting supernatants (100 µL) evaporated under nitrogen at 50°C. The evaporation 
was very brief to reduce the organic content. Complete dryness resulted in poor reconstitution 
and bad measurement reproducibility. The evaporated samples were reconstituted in water (150 
µL) prior to UPLC-MS/MS quantification of cimetidine sulfoxide using the Xevo TQ-S triple-
quadrupole MS operated under positive electrospray ion mode. Analytes were separated on a 
reversed-phase analytical column (Thermo Scientific Aquasil C18, 2.1 × 50 mm, 3 µm; 
Bellefonte, PA). The gradient (0.4 mL/min) began at 0% B for 0.5 min, then quickly increased to 
5% B and was held there for 3 min. The column was washed with 100% B for 1 min and re-
equilibrated at 0% B for 0.5 min prior to the next injection. UPLC-MRM quantification was 
performed using the peak area ratios of cimetidine sulfoxide to famotidine sulfoxide. Cimetidine 
sulfoxide calibration standards ranged from 0.1 to 100 µM. Cimetidine sulfoxidation rates were 
determined from the amount of metabolite generated between the 1 and 5 min reaction times. 
Cimetidine sulfoxide formation was linear for a minimum of 30 min under the described 
conditions (data not shown). Since FMO enzymes are heat labile in the absence of NADPH, their 
stability was examined during the pre-incubation (5 min at 33°C) with substrate only. Results 
showed no significant difference in cimetidine sulfoxidation activities of recombinant FMO1, 
FMO3, and the pooled HLM between pre-incubation with substrate cimetidine only and pre-
incubation with NADPH (data not shown), indicating stability of FMO enzymes during the pre-
incubation with substrate only. The CYP2C9 and CYP2C19 specific activities were provided 
from vendor.  
2.2.8 Data Analysis. The final FMO and CYP2C protein concentrations were the average value 
determined using two signature peptides for each protein. All average values were calculated as 
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the mean. The slope and Y-intercept values were determined by least-square linear regression 
analysis. Student’s t tests (two-tailed, unpaired) were used to compare the pairs of signature 




2.3 Results  
2.3.1 Verification of FMO Signature Peptides by Post-In Silico Product Ion Screening. 
After the initial in silico selection of human FMO3 signature peptides, eight candidate peptides 
(Table 2) satisfied every selection criteria described previously (4, 14). To select the final 
signature peptides (two for each protein) from the candidate peptides, recombinant FMO3 was 
reduced, alkylated and trypsinized, and the resulting digest separated on a UPLC analytical 
column. Analysis was completed through product ion screening of the doubly charged ions of the 
candidate peptides. Representative EPI chromatograms of predicted y ions for the two final 
FMO3 signature peptides selected for use in this study (FMO3_pep1_L and FMO3_pep4_L; 
Table 1) are shown in Figures 1A and 1B, respectively. The signature peptides produced salient 
peaks in each EPI chromatogram (2.5 min peak for FMO3_pep1_L and 5.5 min peak for 
FMO3_pep4_L) and the product ion mass spectra integrated across the peaks matched each 
peptide sequence (Figures 1C and 1D). In addition, EPI chromatograms of predicted y ions for 
the remaining six FMO3 candidate signature peptides are shown in Figure 1. Likewise, EPI 
chromatograms of predicted y ions for the final FMO1, FMO5, CYP2C9, and CYP2C19 
signature peptides (Table 3) also were examined and verified for optimal UPLC-MRM detection 




Figure 1. Post-in silico product ion screening of FMO3 signature peptides (FMO3_pep1_L 
and FMO3_pep4_L). Extracted product ion chromatograms of predicted y ions (A and B) and 
MS/MS spectra (C and D) of the detected FMO3 signature peptides are shown following product 
ion screening analysis of a recombinant FMO3 Supersomes tryptic digest (40.5 pmol FMO or 50 
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FMO1 FMO1_pep1_L FTEHVEEGR 43-51 1104.2 552.5 589.3 (y5) 
  FMO1_pep1_H FTEHVEEG(R)   1114.2 557.5 599.3 (y5) 
  FMO1_pep2_L VEDGQASLYK 
345-
354 
1110.2 555.5 881.5 (y8) 
  FMO1_pep2_H VEDGQASLY(K) 1118.2 559.6 889.5 (y8) 
              
FMO3 FMO3_pep1_L FSDHAEEGR 43-51 1048.1 524.5 561.3 (y5) 
  FMO3_pep1_H FSDHAEEG(R)   1058.1 529.5 571.3 (y5) 
  FMO3_pep4_L SNDIGGLWK 34-42 990.1 495.4 560.3 (y5) 
  FMO3_pep4_H SNDIGGLW(K)   998.1 499.4 568.3 (y5) 
              
FMO5 FMO5_pep1_L FQENPEEGR 44-52 1106.1 553.4 587.3 (y5) 
  FMO5_pep1_H FQENPEEG(R)   1116.1 558.4 597.3 (y5) 
  FMO5_pep6_L WATQVFK 
388-
394 
880 440.5 622.4 (y5) 
  FMO5_pep6_H WATQVF(K)   888 444.5 630.4 (y5) 
              
CYP2C9 CYP2C9_pep1_L GIFPLAER 98-105 903.2 452.1 585.3 
  CYP2C9_pep1_H GIFPLAE(R)   913.1 456.8 595.3 
  CYP2C9_pep2_L SLVDPK 
460-
465 
656.8 328.9 456.3 
  CYP2C9_pep2_H SLVDP(K)   666.8 333.9 466.3 
              
CYP2C19 CYP2C19_pep1_L GHFPLAER 98-105 917.2 459.1 585.3 
  CYP2C19_pep1_H GHFPLAE(R)   937.1 469.0 595.3 
a
 L and H indicate unlabeled and stable isotope-labeled peptides, 
respectively. 
  b Stable isotope-labeled amino acid residues are included in parentheses.  
 
 c Start and end residue positions of peptides in the corresponding full-length protein.  
 d Theoretical average mass of mono-protonated molecular ion. 
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After identification and verification of the predicted signature peptides, unlabeled signature 
peptides and corresponding 13C and 15N stable isotope-labeled signature peptides (Table 3) were 
synthesized and used for the development and optimization of an UPLC-MRM method. This 
method allows for the multiplexed detection and quantification of FMOs and CYP2Cs in HLM. 
Representative UPLC-MRM chromatograms of signature peptides in tryptic digests of adult 
HLM and fetal HLM are shown in Figure 2.  
 
Figure 2. Representative MRM chromatograms of FMO signature peptides in tryptic 
digests of (A) adult and (B) fetal HLM. Digestion mixtures, containing 30 μg HLM and 1 μg 
trypsin, were incubated for 4 h at 37°C prior to UPLC-MRM analysis.   


















































2.3.2 Effects of Trypsin Digestion Time and Protein:Trypsin Ratio. To optimize trypsin 
digestion conditions and determine the dynamic range, the effects of digestion time and 
protein:trypsin ratio on the absolute quantification of FMOs and CYP2Cs in pooled HLM were 
evaluated using the developed UPLC-MRM method. The relative UPLC-MRM signals of the 
signature peptides reached a maximum after 4 h of digestion and plateaued (or decreased slightly 
in some cases) thereafter (Figures 3A, 3B, and 3C). Due to low expression of FMO1 in pooled 
HLM, only one of the two FMO1 signature peptides was detected and evaluated (Figure 3B). As 
a result, tryptic digestion was carried out for 4 h for the remainder of the study. In addition, the 
relative UPLC-MRM signals of the signature peptides increased linearly with respect to HLM 
protein loading between 10 μg to 100 μg when 1 μg trypsin was used (Figures 3D, 3E, and 3F); 
however, a slight downward deviation was noticed above 50 μg of HLM protein. Thus, 
optimized trypsin digestion conditions, 4 h digestion and 30:1 protein:trypsin ratio, were selected 





Figure 3. Effects of trypsin digestion time and HLM protein loading on the UPLC-MRM 
signals of FMO and CYP2C signature peptides derived from pooled HLM. The UPLC-
MRM peak areas of FMO and CYP2C signature peptides were normalized by those of 
corresponding stable isotope-labeled signature peptides spiked in as IS. For the digestion time 
study (A and B), each reaction contained 30 μg of pooled HLM and 1 μg of trypsin. For the 
protein loading study (C and D), each reaction contained 1 μg of trypsin and varying amounts of 
HLM proteins. Symbols and error bars represent the mean and standard deviation of triplicate 
determinations. In many cases, error bars are too small to be seen. Dashed lines (C and D) 

















































































































































































































































































2.3.3 Absolute Quantification of FMO3 and FMO5 in HLM and Correlation to Marker 
Substrate Activity. Similar to the immunoquantification and targeted proteomic quantification 
of CYPs (4, 15), recombinant FMO Supersomes of known concentrations were used initially to 
create calibration standards. The concentrations of the recombinant FMO Supersomes, based on 
FAD content, were provided by the vendor. The calibration curves for each recombinant FMO 
Supersome (0.01 to 4 pmol/ digestion; 10-12 concentrations) demonstrated good linearity (r2 > 
0.99). Using 30 μg of HLM, the observed lower limit of quantification for the three FMOs was 
0.33 pmol/mg HLM protein. The intraday accuracy (percent deviation) and precision (CV) of the 
analytical method, based on QC samples, were within 15%.  
Method coherence was evaluated by comparing protein quantification results from two different 
signature peptides of the same protein (i.e., CYP2C9_pep1_L vs. CYP2C9_pep2_L; 
FMO3_pep1_L vs. FMO3_pep4_L and FMO5_pep1_L vs. FMO5_pep6_L). In each case, a 
strong correlation, near-unity slope and near-zero Y-intercept were observed (Figures 4B, 4C, 
and 4D), indicating consistent protein quantification results between the different signature 
peptides. In addition, good coherence was observed for two FMO1 signature peptides when fetal 
HLM were analyzed (Figure 4A; described below). As a result, final protein concentrations were 





Figure 4. Coherence analysis of FMO and CYP2C9 protein quantification by UPLC-MRM-
based targeted proteomic approach using different signature peptides and recombinant 
FMO Supersomes-generated calibration standards. Quantification of FMO1 was performed 
using the fetal HLM panel, whereas quantification CYP2C9, FMO3, and FMO5 was performed 
using the adult HLM panel. Symbols and error bars represent the mean and standard deviation of 
triplicate determinations for an individual donor HLM. In many cases, error bars are too small to 
be seen. Dotted lines represent the best-fit lines of least-square linear regression analysis.  
A) B) 
C) 


















































































































































































Using a panel of adult HLM (n = 9 individual donors and 1 pooled), the protein concentrations of 
the three FMOs were determined using the developed targeted quantitative proteomic method. 
The FMO1 concentration in adult HLM was below the lower limit of quantification (<0.33 
pmol/mg HLM protein). The final FMO3 and FMO5 average protein concentrations (range and 
95% confidence interval [CI]) were 46 (26 – 65 and 36 – 56) and 27 (11.5 – 49 and 18.5 – 36) 
pmol/mg HLM protein, respectively. The CYP2C9 and CYP2C19 average protein concentrations 
(range) were 71.0 (41.8-108.8) and 6.4 (1.1- 16.8) pmol/mg HLM. Furthermore, cimetidine 
sulfoxidation activities were measured in the HLM panel and compared to FMO protein 
concentrations. A strong correlation was observed between cimetidine sulfoxidation activity and 
FMO3 protein concentration (r2 = 0.86, P = 0.0001; Figure 5A), but not FMO5 protein 
concentration (r2 = 0.30, P = 0.103; Figure 5B). Specific activities of CYP2C9 and CYP2C19 are 
provided from the vendor. Strong quantity and activity correlations were also seen in both 





Figure 5. Correlation analysis of FMO and CYP2C protein content and measured marker 
activity in (A) (C) (D) adult and (B) fetal individual donor HLM panels. Symbols and error 
bars represent the mean and standard deviation of triplicate determinations for an individual 
donor HLM. In many cases, error bars for protein concentration are too small to be seen. Dotted 
lines represent the best-fit lines of least-square linear regression analysis.  
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2.3.4 Comparison of Recombinant Proteins vs. Synthetic Peptides as Calibration Standards 
for Absolute Quantification. Previously, our laboratory and others have reported signature 
peptide-dependent absolute quantification of CYPs and drug transporters using synthetic 
peptides as calibration standards (4, 14, 15, 19, 20). To assess such a scenario for the absolute 
quantification of FMOs, two signature peptides were selected for each FMO isozyme (Table 1) 
and quantification coherence between the two peptides was evaluated. When recombinant FMO 
Supersomes of known concentration were used to generate signature peptide standards, good 
coherence was observed, as described above (Figure 4). However, when synthetic peptides of 
known concentrations were used to generate signature peptide standards, good coherence was 
observed for FMO1, but not for FMO3 or FMO5 (Figure 6). 
 
 
Figure 6. Comparison of FMO protein quantification by UPLC-MRM-based targeted 
proteomic approach using different signature peptides and synthetic signature peptide-
generated calibration standards. Symbols represent the mean of triplicate determinations for 
an individual donor HLM. Lines and error bars represent the mean and standard deviation for a 
panel of HLM. Student’s t tests (two-tailed, unpaired) were used to compare the pairs of 
























































































































P = 0.042C) 
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Absolute FMO concentrations measured using synthetic peptide standards were substantially 
greater than those determined using recombinant protein standards (i.e., Supersomes) (Figure 6 
vs. Figure 4). For example, the average FMO3 and FMO5 concentrations in adult HLMs were 46 
and 27 pmol/mg HLM protein, respectively, with recombinant protein standards. In contrast, 
they were 259 or 412 pmol/mg HLM protein (5.6- to 9-fold higher) for FMO3 with synthetic 
FMO3_pep1_L or FMO3_pep4_L standards and 21 or 32 pmol/mg HLM protein (0.8- to 1.2-
fold higher) for FMO5 with synthetic FMO5_pep1_L or FMO5_pep6_L standards. 
2.3.5 Absolute Quantification of FMOs in Recombinant FMO Supersomes using Synthetic 
Peptide-generated Calibration Standards. To further investigate discrepancies in the absolute 
quantification of FMOs when recombinant proteins vs. synthetic peptides were used as standards, 
and determine the ratios of holoprotein vs. total protein, total FMO protein was quantified in 
recombinant FMO Supersomes of different concentrations using synthetic peptides as calibration 
standards. The measured total FMO protein amount was plotted against the nominal FMO 
protein amount based on FAD content, which represents the FMO holoprotein (Figure 7). 
Similar to the previously described signature peptide-dependent quantification, the ratio of total 
protein vs. holoprotein (slopes in Figure 8) for each recombinant FMO Supersomes also was 
dependent upon the signature peptide used. The ratio ranged from 5.0 to 5.6 for FMO1, 6.0 to 8.4 





Figure 7. Comparison between total (holoprotein + apoprotein) FMO protein concentration 
and nominal holoprotein concentration in FMO Supersomes. The total FMO protein 
concentration was determined using synthetic signature peptides as calibration standards, while 
the nominal holoprotein concentration was determined based on FAD content (provided by the 
vendor). Dotted lines represent the best-fit lines of least-square linear regression analysis.  
 
  
A) B) C) 






































































































































In this study, a UPLC-MRM-based targeted quantitative proteomic method has been developed 
for the multiplexed absolute quantification of FMOs 1, 3 and 5, and CYP2C9 and 2C19 in HLM. 
This method has a lower limit of quantification of 0.33 pmol/mg HLM protein for each FMO 
when 30 µg of HLM is used.  
LC-MRM-based targeted quantitative proteomic methods for the absolute quantification of 
CYPs, UGTs and drug transporters were first reported in the late 2000s (4, 11-13). These 
methods rely on the identification and detection of signature peptides for each target protein. The 
selection and verification of suitable signature peptides can be time-consuming and costly, 
mainly due to peptide synthesis after in silico selection. The ability to verify LC-MRM detection 
of the selected signature peptides in a protein digest prior to committing to peptide synthesis is 
therefore desirable. As such, we implemented a post-in silico product ion screening step to verify 
the detection of selected signature peptides (Figure 1) prior to their synthesis in order to reduce 
unnecessary peptide synthesis and costs. For example, only two FMO3 signature peptides 
(FMO3_pep1_L and FMO3_pep4_L) were synthesized in this study, rather than all eight 
candidate signature peptides (Table 2).  
To achieve absolute quantification using an LC-MRM-based targeted proteomic approach, two 
types of standards are typically employed, recombinant proteins of known concentration or 
synthetic signature peptides of known concentration. Due to the poor coherence (i.e., signature 
peptide-dependent quantification) when synthetic peptides were employed as standards (4, 14, 
15, 19, 20), we prefer to use recombinant proteins when available (e.g., CYPs) to generate 
standards and employ at least two signature peptides for each protein to ensure quantification 
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coherence. Quantification was coherent between signature peptides for all three FMOs when 
recombinant FMO Supersomes were used to generate standards (Figure 4). Therefore, we 
recommend the use of recombinant proteins, when available, to generate standards for LC-
MRM-based targeted protein quantification. Moreover, we call for a coordinated effort to 
produce reference protein standards, especially in the case of drug transporters, for use as 
calibration standards for targeted quantitative proteomics. It is not completely understood yet 
what may cause the lack of coherence in signature peptide-dependent quantification when 
synthetic peptides are used as standards. We have proposed that different digestion efficiencies 
(e.g., missed cleavage) and/or unexpected post-translational modifications of signature peptides 
were the underlying causes (14), and warrant future investigation. 
FMOs, specifically the holoprotein, require an FAD prosthetic group for catalytic activity. 
Recombinant FMO Supersomes can be quantified based on their FAD content to give a 
holoprotein concentration. In contrast, the use of synthetic peptides as standards for targeted 
proteomic quantification provides a total protein concentration (i.e., holoprotein + apoprotein) 
for a sample. Such a distinction was seen (Figure 8), as the total FMO protein amount exceeded 
its nominal holoprotein amount 5- to 6.6-fold for FMO1 and 6- to 8.5-fold for FMO3, while only 
a small difference (0.9- to 1.5-fold) was seen for FMO5. These results suggest that a large 
portion of FMO1 and FMO3 proteins in Supersomes are present as apoprotein without the FAD 
prosthetic group, whereas most FMO5 proteins are holoproteins. This is consistent with a much 
greater FAD content in FMO5 Supersomes (2700 pmol/mg protein; lot#3154943) relative to 
those in FMO1 and FMO3 Supersomes (500 and 810 pmol/mg protein, respectively; 
lot#3098891 and lot#3130681, respectively) reported by the vendor, although differential 
expression efficiency also could contribute to FAD content differences in FMO Supersomes. 
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For both conventional immunoquantification and the targeted proteomic quantification described 
here, an assumption was made that the holoprotein:apoprotein ratio remains the same between a 
recombinant system (e.g., Supersomes) and HLM. However, this assumption remains to be 
examined. Deviation from this assumption could result in either underestimation or 
overestimation of enzymatic activity in HLM, depending on how the ratio in HLM deviates 
relative to that in the recombinant system. For example, if the ratio deviates upward in HLM 
(i.e., higher proportion of holoproteins), this will result in an underestimation of HLM 
holoprotein concentration and the measured HLM activity will exceed the predicted activity 
calculated as the product of recombinant enzyme activity and HLM protein expression. To test 
this, one could first determine the rate of a probe substrate reaction, which needs to be catalyzed 
exclusively by the enzyme of interest, in HLM and then compare the measured HLM activity 
with the predicted activity based on the measured activity of the recombinant enzyme and 
measured expression level of the enzyme in HLM. Using FMO3 and cimetidine sulfoxidation as 
an example, the average measured cimetidine sulfoxidation activity in the adult HLM panel was 
1.25 nmol/min/mg HLM (Figure 5A), the measured cimetidine sulfoxidation activity of 
recombinant FMO3 was 6.0 nmol/min/nmol FMO3 (unpublished data), and the measured FMO3 
expression in HLM was 0.046 nmol/mg HLM (Figure 4B). The predicted activity is 0.28 
nmol/min/mg HLM, substantially less than the measured activity of 1.25 nmol/min/mg HLM. 
Thus, an upward deviation of the holoprotein:apoprotein ratio in HLMs could have contributed 
to the under-prediction, in addition to other possibilities proposed in a companion study (21). 
The questionable assumption regarding the holoprotein:apoprotein ratio for FMOs, as well as for 
CYPs, is underappreciated and requires further investigation using newly available analytical 
tools (e.g., targeted quantitative proteomics). 
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In summary, a UPLC-MRM-based targeted proteomic assay has been developed for the absolute 
protein quantification of FMOs 1, 3, 5, CYP2C9 and 2C19 in HLM. The developed FMO and 
CYP2C assay and other previously developed targeted quantitative proteomic assays are 
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Human hepatic CYPs and FMOs undergo age-dependent changes in expression, or ontogenetic 
processes, which affect the pharmacokinetics, toxicity and efficacy of drugs metabolized by 
these enzymes. Therefore, dose justifications are frequently needed for patients of varying ages. 
In the past, accurate measurements of CYP and FMO ontogenies were difficult, because of a lack 
of specific targeting antibodies. For example, there is no antibody available commercially to 
differentiate between CYP4F2 and CYP4F3B, which share 93% amino acid sequence identity 
(1). In addition, DMEs also tend to have overlapping activities, making it difficult to differentiate 
between isoforms. For example, 7-ethoxyresorufin O-deethylation is a widely accepted 
measurement of CYP1 subfamily activity, but it cannot discriminate between CYP1A1, CYP1A2 
and CYP1B1. FMO1 and FMO3 both mediate the sulfoxidation of cimetidine, producing the 
same metabolite; this activity cannot be used to differentiate between the two isoforms (2). 
Another difficulty in determining ontogeny is the limited number of proteins that can be assessed 
at one time. As a result, analytical assays with high specificity and multiplexing are in demand 
for the study of human hepatic ontogeny.  
An MS-based targeted strategy for protein quantification was first published in 2003 by S. A. 
Gerber et. al. (3). It was developed first in 2008 for the absolute quantification of human hepatic 
CYP3As by M. Z. Wang et al. (4). Since then, MS-based targeted protein quantification has been 
adopted for the measurement of CYPs, FMOs, UGTs and drug transporters, and has been widely 
accepted for protein quantification (1, 2, 4-7). Before applying targeted proteomics for the 
discovery of new ontogeny patterns, the known patterns must be confirmed.   
The ontogenies of human hepatic CYP3A, CYP2C, and FMO have been studied by Western 
blot. J. C. Stevens et. al. studied CYP3A ontogeny in HLMs from 212 individuals ranging in age 
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from the 1st trimester up to 9 years (8). He found that CYP3A5 was highly variable and that the 
variability occurred independent of age; CYP3A7 had extremely high expression at 158-311 
pmole/mg fetal liver, but it dropped quickly after birth; CYP3A4 had little expression prior to 
birth and increased at postnatal ages.  
CYP2C ontogeny was reported by S. B. Koukouritaki et. al. in 2003. HLM from 237 subjects, 
ranging from 8 months gestation up to 18 years of age, were analyzed by Western blot and 
activity assays (9). Hepatic CYP2C9 expression values during the first trimester start at 1-2% of 
the average adult level. Expression increased during the second and third trimesters to 30% of 
the adult average. However, CYP2C9 variability is much greater in adult liver, up to 35-fold. 
CYP2C19 was measurable starting at 8 weeks gestation and was 12-15% of the average adult 
level. After birth, expression increased rapidly. There was a 25-fold variation in CYP2C19 
expression.  
Hepatic FMO1 and FMO3 undergo a developmental switch similar to that of CYP3A7 and 
CYP3A4. FMO1, the major fetal isozyme, peaks early in gestation (first and second trimesters) 
and decreases gradually to undetectable at birth (10). In contrast, expression of FMO3, the major 
adult isozyme, turns on after birth and increases over time, reaching an adult level in the early 
teenage years (10). This differential enzyme expression has garnered much attention, specifically 
for the dose adjustment of FMO substrate drugs in infants and children (11, 12). FMO5 mRNA 
expression exceeds that of FMO3 in adult liver (13); however, earlier reports suggested the 
opposite (14, 15). Additionally, FMO5 mRNA expression in fetal livers is approximately one-
sixth of that in adult livers (13).  
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Due to the lack of specificity and poor multiplexing capability of immuno-blotting assays, the 
ontogenies of many important CYPs remain unknown, especially those of CYP4F2, CYP4F3B 
and FMO5. CYP4Fs are the third most abundant CYP in the human liver and are responsible for 
the metabolism of multiple important endogenous molecules (e.g., arachidonic acid, vitamin K1 
and vitamin E), drugs (e.g. fingolimod), and xenobiotics (e.g. DB289 and DB868). The 
expression, activity and endogenous biological function(s) of FMO5 are unknown.  
The multiplexing capabilities and specificity of LC-MRM-based targeted proteomics has allowed 
the absolute quantifications of CYP2C9, 2C19, 3A4, 3A5, 3A7, 4F2 and 4F3B, and FMO1, 3 
and 5 to be completed within a single run needing only 30 ug of HLM protein. The quantification 
of these enzymes was based on well-validated assays developed in our laboratory (1, 2, 4). The 
goal of this chapter is to determine the ontogenies of CYP2C9, 2C19, 3A4, 3A5, 3A7, 4F2 and 
4F3B, and FMO1, 3 and 5 by LC-MRM-based targeted proteomics using fetal, pediatric and 





3.2 Materials and Methods 
3.2.1 Chemicals, Enzymes, and Liver Tissues. Optima-grade acetonitrile, water, formic acid, 
and acetic acid were obtained from Fisher Scientific (Pittsburgh, PA). Ammonium bicarbonate, 
dimethyl sulfoxide, dithiothreitol, and iodoacetamide were purchased from Sigma-Aldrich (Saint 
Louis, MO). Recombinant human FMO1, FMO3, FMO5, CYP2C9, CYP2C19, CYP3A4, 
CYP3A5, CYP3A7, CYP4F2 and CYP4F3B Supersomes™, prepared from baculovirus-infected 
insect cells expressing human FMO and CYP enzymes, were purchased from Corning Gentest 
(Woburn, MA). The FMO or CYP concentration of each Supersomes (pmol/mL and pmol/mg 
protein), based on the FAD or heme content determined by an HPLC-fluorescence method or CO 
difference spectrum assay (16, 17), was provided by the supplier. Synthetic 13C and 15N stable 
isotope-labeled crude signature peptides were acquired from Thermo Scientific (Ulm, Germany). 
All synthetic peptide sequences were confirmed by MS/MS fragmentation analysis using a 
Waters Xevo TQ-S triple-quadrupole MS (Milford, MA). Sequencing-grade modified trypsin 
was purchased from Promega (Madison, WI). Liver tissues from seven fetal (14-20 weeks 
gestation), sixteen pediatric (5 months-10 years), and ten adult (22-80 years) donors were 
obtained from the NICHD Brain and Tissue Bank for Developmental Disorders (Contract 
#HHSN275200900011C, Ref. No. NO1-HD-9-0011; Baltimore, MD) under an approved UNC-
Chapel Hill IRB and were used to prepare fetal, pediatric, and adult HLM (Table 4). The liver 
samples were kindly shared by our collaborators from UNC-Chapel Hill, Nicole R. Zane Ph.D., 




Table 4. Individual HLM donor information. 
Group Sample Gender Age Race
A1 54 years Male Caucasian
A2 40 years Female Caucasian
A4 23 years Male Hispanic
A5 23 years Male Hispanic
A7 80 years Male Caucasian
A8 22 years Female Caucasian
A9 32 years Female Caucasian
A10 46 years Female Caucasian
A11 45 years Female Caucasian
A12 32 years Female Caucasian
F1 Female 18 weeks African American
F5 Male 15 weeks African American
F6 Female 20 weeks African American
F7 Male 16 weeks African American
F8 Male 15 weeks African American
F9 Male 19 weeks Caucasian
F10 Male 16 weeks African American
P1 Male 6 years Caucasian
P2 Male 4 years Caucasian
P3 Male 2 years African American
P4 unknown 2 years unknown
P5 unknown 1 years unknown
P6 unknown 4 months unknown
P7 Male 4 years Caucasian
P8 Male 8 years Caucasian
P9 Male 2 years African American
P10 Female 9 years Hispanic
P11 Female 111 days Caucasian
P12 Female 92 days Caucasian
P13 Male 63 days African American
P14 Female 57 days African American
P15 Female 97 days African American
P16 Male 71 days African American









3.2.2 Trypsin Digestion. The tryptic digestion of FMO Supersomes and HLM was performed as 
described previously with minor modifications (1, 4). Briefly, protein samples (30 μg) were 
reduced in ammonium bicarbonate buffer (pH 8.0, 50 mM final concentration) containing 
dithiothreitol (4 mM final concentration) and heated at 60°C for 60 min to denature the proteins. 
After cooling to room temperature, the samples (90 μL total volume) were alkylated with 
iodoacetamide (10 mM final concentration) for 20 min in the dark prior to digestion with 1 µg 
trypsin at 37°C for 4 h unless stated otherwise. All reactions were carried out in Eppendorf 
Protein LoBind microcentrifuge tubes (Hamburg, Germany) to minimize protein and peptide loss 
due to binding. Solvent evaporation during the incubations was minimized by sealing the capped 
tubes with parafilm and applying pressure with an aluminum block. 
3.2.3 UPLC-MRM Analysis. Lyophilized stable isotope-labeled signature peptides were 
dissolved in 1 mL of 1:1 (v/v) acetonitrile:water solution. The solution was diluted further to 
approximately 2-4 μg/mL and then infused into the Xevo TQ-S MS at 5 μL/min with an LC flow 
of 50% B at 0.4 mL/min. MRM parameters were optimized using IntelliStart (Waters) under 
positive electrospray ion mode: capillary voltage, 1.5 kV; cone voltage, 40 V; source offset, 40 
V; dissolvation temperature, 500°C; dissolvation gas, 1000 L/h; nebulizer gas, 7 bar. The 
optimum collision energy and precursor/production masses for the signature peptides are 
summarized in Table 3 or from previous publications (1, 2, 4). UPLC-MRM quantification was 
performed using the peak area ratios of signature peptides to corresponding stable isotope-
labeled signature peptides (internal standards). 
3.2.4 Preparation of Calibration Standards. Recombinant FMO1, FMO3, FMO5, CYP2C9, 
CYP2C19, CYP3A4, CYP3A5, CYP3A7, CYP4F2, and CYP4F3B Supersomes of known 
concentrations were used to create calibration standards. All recombinant protein standards were 
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denatured, alkylated and trypsin-digested as described above, prior to UPLC-MRM analysis. Due 
to the varying amount of total proteins in the standards, additional trypsin (2 µg total) was used 
to keep the protein:trypsin ratio ≤ 30:1 in the high concentration standards.  
3.2.5 Data Analysis. The final protein concentrations were the average value determined using 
two signature peptides for each protein. All average values were calculated as the mean. The 
slope and Y-intercept values were determined by least-square linear regression analysis. 
Student’s t tests (two-tailed, unpaired) were used to compare the pairs of signature peptides. All 




3.3 Results  
3.3.1 Peptide Separation and Detection. The UPLC-MRM method used in this study was 
developed by building upon the LC-MRM method described previously by M. Z. Wang et. al. 
2008 (4). The original LC method was selected for the co-elution of all peptides with a quick 3.5 
min gradient to allow for fast analysis, as CYP3A4 and CYP3A5 are expressed quite abundantly 
in adult human livers. However, the detection and quantification of enzymes for the study of 
ontogenesis requires a high degree of measurement sensitivity, something that may be 
compromised by the inhibition of ionization when all peptides are eluted together. Therefore, the 
current study utilized a UPLC column and 13.5 min gradient with the goals to achieve better 
peptide separation and minimize ion suppression (Figure 8). The UPLC-MRM settings were 




Figure 8. UPLC-MRM chromatograms of stable isotope-labeled signature peptides (internal 
standards) for quantification of CYPs (A) and FMOs (B).  
 
3.3.2 Ontogenies of CYPs 3A4, 3A5, and 3A7. A previous study demonstrated the specificity 
of the LC-MRM-based targeted quantification method for CYP3A4 and CYP3A5, and its strong 
correlation to Western blots and substrate activity assays (4). A unique CYP3A7 signature 
peptide has been added in this study to take advantage of the adaptability and multiplexing of the 
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LC-MRM-based method, while at the same time, cross-validating the ontogenies of CYP3A 
family members quantified previously.  
Fetal hepatic CYP3A4 (Figure 9) and CYP3A5 (Figure 10) averaged (range) 1.2 (0.9-1.3) and 
5.0 (0.6-14) pmol/mg HLM protein (n=7 donors), respectively, which are significantly lower 
than the highly expressed CYP3A7 (Figure 11) average (range) of 536.5 (454.4-645.6) pmol/mg 
HLM protein. The developmental switch between CYP3A7 and CYP3A4 happened after birth; 
CYP3A7 slowly decreased during the pediatric stage while CYP3A4 gradually increased (n=16 
donors). CYP3A7 and CYP3A4 averaged (range) 51.4 (2.5-163.5) and 64.6 (16.2-177.1) 
pmol/mg HLM protein, respectively. In adulthood, CYP3A4 reached an average of 76.2 (17.9-
123.4) pmol/mg HLM protein (n=10 donors), whereas CYP3A7 dropped to 5.1 (1.3-13.1) 
pmol/mg HLM protein after removing the 80 year-old subject. This particular subject expressed 
CYP3A7 at 143.1 pmol/mg HLM protein, 70-fold higher than the average of the other adult 
donors (<55 years old). In comparison, CYP3A5 expression was independent of age, averaging 




Figure 9. Age-dependent CYP3A4expression in human livers. Fetal (N), pediatric (P), and adult 
(A) samples were labeled in blue, green, and red symbols respectively. 
 
Figure 10. Comparison of age-dependent CYP3A4 and CYP3A5 expression  in human livers.  










































































































Figure 11. Age-dependent CYP3A7 expression in human livers. Fetal (N), pediatric (P), and 
adult (A) samples were labeled in blue, green, and red symbols respectively. 
 
3.3.3 Ontogenies of CYPs 2C9 and 2C19.  CYP2C9 and CYP2C19 had a similar trend across 
the age groups (Figure 12). In fetal livers, CYP2C9 and CYP2C19 expression averaged (range) 
1.2 (0.9-1.5) and 0.2 (0.1-0.3) pmol/mg HLM protein, respectively. Expression increased to 51.6 
(20.8-89.8) and 54.4 (30.0-78.1) pmol/mg HLM protein for CYP2C9 and 9 (0.4-34) and 4.3 (0.1-
12.9) pmol/mg HLM protein for CYP2C19 in pediatric and adult tissues, respectively. On 
average, CYP2C9 expression was higher than that of CYP2C19 at all stages of development. The 
variability in CYP2C19 expression was higher in pediatric compared to adult livers, whereas 
CYP2C9 variability was similar.  












































Figure 12. Ontogeny of CYP2C9 and CYP2C19 in human livers. Fetal (N), pediatric (P), and 




























































































3.3.4 Ontogenies of CYPs 4F2 and 4F3B. The method for targeted analysis of CYP4F2 and 
4F3B was established and validated in our laboratory previously (1). The age-dependent 
expression of these enzymes has not been studied due to a lack of specific antibodies and activity 
substrate. With UPLC-MRM, the ontogeny of CYP4F2 and CYP4F3B was determined for the 
first time (Figure 13). CYP4F2 expression followed a pattern/trend similar to that of CYP3A4, 
CYP2C9, and CYP2C19. Expression started at a low of 2.6 (1.2-4.1) pmol/mg HLM protein in 
fetal livers, increased to 13.5 (1.2-28.1) in pediatric tissues, and was maintained at 13.0 (4.2-
33.8) in adult livers. In comparison, CYP4F3B did not change throughout the ages, ranging from 





Figure 13. Age-dependent CYP4F2 and CYP4F3B expression in human livers. Fetal (N), 
pediatric (P), and adult (A) samples were labeled in blue, green, and red symbols respectively. 
 
3.3.5 Ontogenies of FMO1, FMO3, and FMO5. The concentration of FMO1 in adult HLM 


































































































FMO5 average protein concentrations (range and 95% confidence interval [CI]) in adults were 
46 (26 – 65 and 36 – 56) and 27 (11.5 – 49 and 18.5 – 36) pmol/mg HLM protein, respectively. 
In the fetal HLM panel, FMO1 protein concentration averaged (range and 95% CI) 7.0 (4.9 – 9.7 
and 5.2 – 8.7) pmol/mg HLM protein. Appreciable amounts of FMO5 also were present, 
averaging 21 (14 – 32 and 14 – 29) pmol/mg HLM protein (Figure 14A). In contrast to adult 
HLM, FMO3 in fetal HLM was barely above the lower limit of quantification (0.33 pmol/mg 
HLM protein), averaging 0.7 pmol/mg HLM protein with a high concentration of 2.2 pmol/mg 
HLM protein. FMO5 protein concentration averaged (range and 95% CI) was 36.2 (2.9 – 110 
and 20.1 – 52.3) pmol/mg HLM protein in the pediatric HLM panel (Figure 14B). There was no 











































































































































3.4 Conclusions and Discussions 
In this chapter, the ontogenies of human hepatic CYPfCYP2C9, 2C19, 3A4, 3A5, 3A7, 4F2 and 
4F3B, and FMO1, 3, and 5 were quantified simultaneously in fetal, pediatric, and adult livers. 
Each measurement consumed less than 100 μg of HLM protein for biological triplicates of each 
subject, thanks to the sensitivity, multiplexing capabilities, and selectivity of the UPLC-MRM-
based targeted protein quantification method. Among these measured targeted proteins, the 
ontogenies of CYP4F2, CYP4F3B, and FMO5 were determined for the first time.  
3.4.1 CYP3A Ontogeny. CYP3A4 and CYP3A5 account for nearly half of all CYP-mediated 
drug metabolism and close to 30% of expression in adult liver. The expression of each enzyme is 
highly inducible; their transcription is controlled by PXR (pregnane X receptor) and CAR 
(constitutive androstane receptor), both of which respond to a wide range of chemicals. Induction 
factors, such as diet and drug history, contribute greatly to the inter-individual variability of 
CYP3A4 and CYP3A5 expression (18). CYP3A7 expression was first found in the fetal liver in 
1988 (19). However, due to the lack of specific antibodies, the ontogeny of CYP3A family 
members remained unexplored. J. C. Stevens et. al. studied CYP3A ontogeny using over 200 
livers that were donated by subjects ranging in age from the first trimester to 18 years old. 
Equipped with only a CYP3A5-specific antibody, Stevens had to extrapolate CYP3A7 and 
CYP3A4 expression based on DHEA oxidation activity (8). CYP3A7 expression in fetal liver 
was extremely high (158-311 pmol/mg HLM protein). J. S. Leeder et. al. examined 51 fetal 
livers using western blots with a CYP3A4/3A7 cross-reactive antibody and found that CYP3A7 
had an average expression of 232 (20.6-434) pmol/mg HLM protein (20). Our UPLC-MRM-
based targeted proteomics quantification also showed a much greater level of CYP3A7 in fetal 
livers compared to CYP3A expression in adult liver. Our measurement was approximately twice 
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as high, averaging (range) 536.5 (454.4-645.6) pmol/mg HLM protein, compared to that 
determined by Western blots or activity measurements. This inconsistency could be due to 
limited dynamic range of Western blot-based immunoquantification, which tends to 
underestimate highly concentrated samples due to signal saturation. In the current study, we 
found CYP3A5 expression to be independent of age with large inter-individual variability. 
CYP3A4 expression was similar to historical data: very little expression in the fetal liver but 
increases during the pediatric stage until peaking around adulthood. The absolute average was 
different from activity extrapolations and Western blot measurements, just like CYP3A7. 
However, good quantitative consistency was found between the current measurements and those 
done by M. Z. Wang et. al. in 2008; CYP3A4 in adult liver was 64.6 (16.2-177.1) compared to 
67 (9-322) pmol/mg HLM protein while CYP3A5 was 1.5 (0.4-4.7) compared to 4 (0.3 to 20)  
pmol/mg HLM protein, respectively (4). 
3.4.2 CYP2C ontogeny. CYP2C9 and CYP2C19 are more abundantly expressed than the other 
two CYP2C family members, CYP2C8 and CYP2C18. Previous reports stated that there were 
non-detectable CYP2C9 and 2C19 were undetectable in fetal livers (16 to 40 weeks gestation), 
while CYP2C8 and 2C18 were expressed at 10% of the adult CYP2C9 level, suggesting a 
developmental switch in expression. CYP2C9 was detectable 24 hours after birth. The same 
trend was found with the current UPLC-MRM-based quantification method. Unexpectedly, 
Koukouritaki et. al. measured CYP2C9 and CYP2C19 expression to be approximately the same 
level at all stages of development, however targeted proteomics quantified CYP2C9 to be 
approximately 5-10-fold higher than CYP2C19. Our CYP2C9/2C19 ratio was consistent with 
many other reports including those utilizing Western blots (21) and quantitative proteomics (22).  
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3.4.3 CYP4F ontogeny. An LC-MRM-based CYP4F2 and CYP4F3B specific quantitative 
method was established quite recently, in 2014 (1). Prior to that, there were no antibodies able to 
differentiate between the CYP4F isoforms. In addition, even though vitamin K1 ω-oxidation was 
identified as a specific CYP4F2 activity (23), the reaction is extremely slow and the ω-oxidized 
vitamin K1 metabolite is not available; we had no luck observing CYP4F2 activity in this way. 
Because of these combined reasons, CYP4F2 ontogeny had yet to be studied. However, our 
laboratory demonstrated previously that the CYP4F subfamily is the 3rd highest expressed CYP 
in human adult livers. McDonald et. al. showed that hepatic CYP4F2 expression differences 
contribute to inter-individual differences in warfarin dosing (23). Thus, it is of great importance 
to know the absolute quantity of CYP4F enzymes among different age groups.  
With no previous CYP4F ontogeny data to compare to, the current adult CYP4F quantification 
could only be compared to previously quantified CYP4F from a different panel of adult HLMs. 
Among the 31 adult subjects, Michaels et. al. found CYP4F2 to have an average (range) of 14.3 
(1.3–27.1) and CYP4F3B to be 11.3 (6.4–20.9) pmol/mg HLM protein (1), both of which are 
very close to the current averages of 13.0 (4.2-33.8) and 12.5 (6.3-18.3) pmol/mg HLM protein 
for CYPs 4F2 and 4F3B, respectively. 
3.4.4 FMO ontogeny. In adult HLMs, FMO3 was more abundant than FMO5 (46 vs. 27 
pmol/mg HLM protein), supporting earlier reports (14, 15) but not the most recent report (13), 
both of which were based on mRNA expression. In the fetal HLMs (14-20 weeks gestation), 
FMO1 was expressed at relatively high levels (7.0 pmol/mg HLM protein), similar to what was 
reported previously (7.8 pmol/mg HLM protein; 8-15 weeks gestation) (10). Interestingly, FMO5 
was the predominant isozyme in fetal HLM, averaging 3-fold greater protein expression than 
FMO1 (21 vs. 7.0 pmol/mg HLM protein). In the pediatric HLM, FMO5 also appeared to be the 
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predominant isozyme (36.2 vs. 20.0 pmol/mg HLM protein for FMO3), while FMO1 was barely 
detected. Although FMO5 expression was not significantly different among the three age groups, 
larger interindividual variability was observed in the pediatric HLM (38- fold vs. 4.3- and 2.3-
fold in adult and fetal HLM, respectively). These targeted quantitative proteomic results confirm 
previous reports that FMO1 and FMO3 expression undergo a developmental transition and also 
discovered that FMO5 has relatively stable expression throughout development. 
3.4.5 Summary. The ontogenies of multiple CYPs and FMOs were studied in human fetal, 
pediatric, and adult livers. Expression trends observed for CYP3As, CYP2Cs, and FMO1 and 3 
confirm historical reports. The ontogenies of CYP4F2 and 4F3B and FMO5 were discovered for 
the first time. These proteins were quantified together in a single run, owing to the multiplexing 
capability of the modern UPLC-MRM-based proteomic methods. However, these results should 
be interpreted with caution, as our study only included a small number of HLM from each age 
group, fetal samples only represented the second trimester, and neonatal samples (birth to first 
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CYP1B1metabolizes many polycyclic aromatic hydrocarbon-containing procarcinogens, such as 
benzo(a)pyrene and 7,12-dimethylbenz[a]anthracene (1). This enzyme is expressed in many 
types of human cancers, including breast (2), colon (3), prostate (4), endometrium (5) and ovary 
(6). Steroid hormone-related cancers, such as breast, ovarian, uterine and endometrial (7-9), were 
found to have high levels of CYP1B1(10). The capability of CYPs to activate toxins has been 
exploited to treat cancers. Chemotherapy drugs like ifosfamide, cyclophosphamide, and 
dacarbazine are specifically activated by CYP enzymes in tumor tissues (11).  CYP1B1 either is 
absent or at very low levels in corresponding normal tissues, making it an ideal target for 
anticancer prodrug therapies (12-14).  
CYP1B1 shares more than 40% amino acid sequence identity with two closely related enzymes, 
CYP1A1 and CYP1A2. CYP1A2 is expressed at high levels in the liver, while CYP1A1 is 
expressed in extrahepatic organs/tissues. These three enzymes have overlapping substrates, but 
sometimes generate different products. For example, the hormone 17β-estradiol (E2) is oxidized 
by CYP1A1 and CYP1A2 to form primarily 2-OH-estradiol (2E2) (15), which is harmless; 
CYP1B1 converts E2 to 4-OH-estradiol (4E2), which is carcinogenic (16).  
An ideal CYP1B1-dependent anticancer prodrug should not show toxicity following metabolism 
by CYP1A1/1A2, in order to prevent collateral damage to normal tissues. Based on this 
principle, in vitro cell-based screenings of chemical libraries for new CYP1B1-dependent 
prodrugs should include, but not be limited to, two stages: first, prodrug toxicity should be 
demonstrated in in vitro cell models that overexpress CYP1B1 only, and second, qualified 
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compounds need to be screened in normal in vitro cell models that express CYP1A1 and/or 
CYP1A2, displaying a lack of toxicity.  
Presently, compound library screens are hindered by the lack of well-characterized cell lines for 
first stage screening. The human uterus adenocarcinoma cell line KLE, derived from a poorly 
differentiated endometrial cancer, possesses tumorigenic activity in nude mice (17) and has been 
shown to overexpress CYP1B1 (5). However, no absolute activity or protein quantification data 
showing the KLE cell line to solely express CYP1B1 is available. Previous attempts in the 
laboratory to characterize CYP1A and CYP1B1 expression in the cell line using enzymatic 
activity, with estradiol as the substrate, have been unsuccessful, due to the slow enzymatic 
conversion rate and high background of the E2 chemical stock, although new efforts are ongoing 
to improve metabolite extraction using methyl tert-butyl ether (MTBE). This left absolute and 
specific UPLC-MRM-targeted quantification as the only means by which CYP1A1, CYP1A2, 
and CYP1B1 expression in KLE cells could be determined. The goal of this chapter is to 
characterize CYP1A1, CYP1A2, and CYP1B1 expression in the KLE cell line and normal 




4.2 Materials and Methods 
4.2.1 Chemicals, Enzymes, Tissues, and Cells. Dulbecco’s modified Eagle’s medium 
(DMEM), DMEM/F-12 (1:1), and fetal bovine serum (FBS) were purchased from Life 
Technologies (Carlsbad, CA). A BCA protein assay kit was purchased from Pierce 
Biotechnology (Rockford, IL). Optima-grade acetonitrile, water, formic acid, and acetic acid 
were obtained from Fisher Scientific (Pittsburgh, PA). Ammonium bicarbonate, dimethyl 
sulfoxide, dithiothreitol, and iodoacetamide were purchased from Sigma-Aldrich (Saint Louis, 
MO). Recombinant human CYP1A1, CYP1A2, and CYP1B1 Supersomes, prepared from 
baculovirus-infected insect cells expressing human CYP enzymes, were purchased from Corning 
Gentest (Woburn, MA). Synthetic 13C and 15N stable isotope-labeled crude signature peptides 
were acquired from Thermo Scientific (Ulm, Germany). All synthetic peptide sequences were 
confirmed by MS/MS fragmentation analysis using a Waters Xevo TQ-S triple-quadrupole MS 
(Milford, MA). Sequencing-grade modified trypsin was purchased from Promega (Madison, 
WI). Human kidney, liver, and intestinal microsomes were purchased from XenoTech, LLC 
(Lenexa, KS). A slice of human brain frontal cortex was kindly provided by the University of 
Kansas Medical Center (Kansas City, MO). KLE cells were purchased from American Type 
Culture Collection (Manassas, VA). Blank human plasma (collected in K2-EDTA tubes) was 
purchased from Innovative Research (Novi, MI). 
4.2.2 Cell Culture. KLE cells were cultured in DMEM/F-12 (1:1) medium without phenol red 
and supplemented with 10% (v/v) FBS, and were maintained at 37°C with 5% CO2 and 95% 
humidity. The medium was refreshed twice a week. Cells were harvested on different days post-
seeding using TrypLETM Express for the absolute measurement of CYP1B1 quantity.  
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4.2.3 Microsome Isolation from Cell Culture and Human Brain Frontal Cortex Tissues. 
Microsomes from human brain and KLE cells were prepared as reported previously (18) with 
minor modifications. Briefly, cells and brain frontal cortex tissue were homogenized in a buffer 
(pH 7.4) containing 50 mM Tris-HCl, 1 mM EDTA, and a protease inhibitor cocktail (Roche, 
Indianapolis, IN),. Following homogenization, the samples were centrifuged at 10,000 x g for 30 
minutes and the supernatant collected. The supernatant then was centrifuged at 150,000 x g for 
60 minutes. The resulting pellet was resuspended in a buffer (pH 7.4) containing 10 mM 
potassium phosphate and 20% sucrose. Microsomal protein concentration was determined using 
a BCA assay. The microsomes were stored at -80oC.  
4.2.4 Targeted quantitative proteomic method for protein quantification. Targeted 
proteomic quantification of CYP1B1, CYP1A1, and CYP1A2 protein levels in microsomes was 
performed as described previously for other CYP enzymes with minor modifications (19, 20). 
Briefly, protein samples (30 μg) were reduced in an ammonium bicarbonate buffer (pH 8.0; 50 
mM final concentration) containing dithiothreitol (4 mM final concentration) and heated at 60°C 
for 60 min to denature the proteins. After cooling to room temperature, the samples (90 μl total 
volume) were alkylated with iodoacetamide (10 mM final concentration) for 20 min in the dark 
before digestion with 1 µg trypsin at 37°C for 4 h. Recombinant human CYP1A1, CYP1A2, and 
CYP1B1 Supersomes of known concentrations were used to create calibration standards (0.002 
to 5 pmol/digestion). All reactions were carried out in Protein LoBind microcentrifuge tubes 
(Eppendorf, Hamburg, Germany) to minimize protein or peptide loss due to binding. Reactions 
were cold-quenched with storage at -80°C. The signature peptide sequences used were 
ELVALLVR for CYP1B1, GFYIPK for CYP1A1, and YLPNPALQR for CYP1A2. A mixture 
of stable isotope-labeled signature peptides (1 µl; internal standards) were spiked into thawed 
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samples prior to loading into an autosampler (6°C) for UPLC-MRM analysis as described 
previously (19, 20). The mass transitions used during UPLC-MRM analysis were m/z 
456.8571.4 for ELVALLVR, m/z 362.7357.3 for GFYIPK, and m/z 536.6584.4 for 
YLPNPALQR. The lower limit of quantification was 0.07 pmol CYP/mg microsomal protein for 
CYP1B1, CYP1A1 and CYP1A2. 
4.2.5 Data Analysis. All measurements were done in triplicate. Student’s t tests (two-tailed, 
unpaired) were used to compare the pairs of measurements. All data analyses were performed 




4.3 Results and Discussion 
4.3.1 CYP1B1 expression in human brain, plasma, kidney, liver, and intestine. CYP1A1 and 
CYP1A2 are known to be expressed in the human liver and intestines, but not CYP1B1 (19, 21-
23). CYP levels in the human brain, plasma, and kidney are much lower, making these atypical 
sites for drug metabolism. Microsomes isolated from each of these tissues were tested by 
CYP1B1-targeted UPLC-MRM-based absolute quantification for confirmation of historical 
observations, as well as for examining the specificity of the targeted assay in different matrices. 
As shown in Figure 15, the chromatographic peak that eluted at 8.42 min, indicating the presence 
of CYP1B1, was not observed in any of the human tissue samples. Despite the high level of 
sensitivity (LLOQ = 0.07 pmol/mg microsomal protein), the negative CYP1B1 signal from 
different tissue microsomes showed that our absolute protein quantification assay had very good 
target selectivity in different tissue matrices. These results also confirm previous reports that 
normal human tissues express very little or no CYP1B1. Some publications, however, have 
shown an appreciable or dominant amount of CYP1B1 mRNA in human small intestine and 
kidney (21, 22). The lack of correlation between mRNA and protein expression indicates that 
relative mRNA level may not directly translate to corresponding protein expression. This also 
demonstrates the importance of looking at absolute protein quantity when characterizing enzyme 




Figure 15. CYP1B1 expression in different human tissues. CYP1B1 signature peptide signals 
from CYP1B1 recombinant protein standards and human intestinal, hepatic, renal, plasma, and 
brain frontal cortex microsomes detected by UPLC-MRM targeted proteomics. Digests from 







4.3.2 CYP1A1, CYP1A2, and CYP1B1 expression in KLE cell microsomes. KLE cells 
cultured for 9 days post-seeding were harvested and processed for microsome isolation. UPLC-
MRM signals for CYP1B1, CYP1A1, and CYP1A2 recombinant proteins, which serve as 
positive controls, (Figure 16, upper chromatograms) were compared to the signals from KLE 
microsomes (Figure 16, lower chromatograms). CYP1B1 was present in KLE cell microsomes. 
No detectable expression of CYP1A1 or CYP1A2 was found.  
 
Figure 16. CYP1B1, CYP1A1, and CYP1A2 expression in KLE microsomes. Digests from 
each sample, equivalent to 3 μg of protein, were loaded onto the column for separation and MS 
quantification. 
 
As discussed in the introduction, at least two stages of selection should be used when screening 
for CYP1B1-dependent anticancer prodrugs: 1) positive toxicity demonstrated in cell lines solely 
expressing CYP1B1, and 2) a lack of toxicity in normal human cells. Figure 16 clearly shows 
that the KLE cell line fits the first criteria for prodrug screening.  
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4.3.3 Expression of CYP1B1 in KLE cells at different days post-seeding. CYP1B1 protein 
expression increased from day 3 to day 9 post-seeding (0.31 vs. 0.68 pmol/mg microsomes) and 
remained at a similar level on day 14 post-seeding (0.41 pmol/mg microsomes) (Figure 17A). 
Protein expression tracked quite well with mRNA expression in the KLE cells at different days 
post-seeding (Figure 17B; generated and kindly provided by Zhiying Wang, Ph.D.).  
 
Figure 17. CYP1B1 expression in KLE cells at different days post-seeding. CYP1B1 protein 
expression (A) was quantified by UPLC-MRM-targeted proteomics. Chromatographic peak 
areas of KLE microsomal digest were compared to those from serial concentrations of CYP1B1 
recombinant protein digests, allowing the CYP1B1 concentration in KLE microsomes to be 
extrapolated. CYP1B1 mRNA expression (B) on days 5-13 post-seeding were measured by RT-
PCR.  
 
These results show that the best window for CYP1B1-dependent prodrug screening using KLE 
cells would be approximately 9 days post-seeding, when CYP1B1 protein expression is the 
highest. However, an appreciable amount of CYP1B1 expression did last for at least two weeks. 
Dr. Zhiying Wang also transiently transfected CYP1B1 into human HEK293 cells and measured 
CYP1B1 mRNA expression at different days post-transfection (Wang, Z., Chen, Y., and Wang. 





























M. Z.; J Biomol Screen (under 3rd review)). Her results showed that KLE cells were superior to 
transiently transfected HEK293T cells as CYP1B1 expression quickly diminished in the 
transfected cells. 
4.3.4 Summary. Absolute CYP1 expression in KLE cells was quantified for the first time using 
a UPLC-MRM-targeted proteomic approach. Quantification showed that KLE cells lack 
CYP1A1 and CYP1A2 expression, which are found in normal human organs/tissues. An 
appreciable amount of CYP1B1, which is usually found in many steroid-related human tumor 
tissues, was expressed. The highest CYP1B1 expression in KLE cells occurred around day 9 
post-seeding, but an appreciable amount was seen for at least two weeks. In conclusion, KLE 






1. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, et al. Activation 
of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 
1996;56(13):2979-84. 
2. McKay JA, Melvin WT, Ah-See AK, Ewen SW, Greenlee WF, Marcus CB, et al. 
Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett. 1995;374(2):270-2. 
3. Gibson P, Gill JH, Khan PA, Seargent JM, Martin SW, Batman PA, et al. Cytochrome 
P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal 
colon: implications for drug development. Mol Cancer Ther. 2003;2(6):527-34. 
4. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, et al. Cytochrome 
P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer 
Res. 2005;11(16):5793-801. 
5. Saini S, Hirata H, Majid S, Dahiya R. Functional significance of cytochrome P450 1B1 in 
endometrial carcinogenesis. Cancer Res. 2009;69(17):7038-45. 
6. McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE, et al. 
Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J 
Cancer. 2001;85(2):242-6. 
7. Liu JY, Yang Y, Liu ZZ, Xie JJ, Du YP, Wang W. Association between the CYP1B1 
polymorphisms and risk of cancer: a meta-analysis. Mol Genet Genomics. 2015;290(2):739-65. 
8. Li C, Long B, Qin X, Li W, Zhou Y. Cytochrome P1B1 (CYP1B1) polymorphisms and 
cancer risk: a meta-analysis of 52 studies. Toxicology. 2015;327:77-86. 
9. Zhang H, Li L, Xu Y. CYP1B1 polymorphisms and susceptibility to prostate cancer: a 
meta-analysis. PloS one. 2013;8(7):e68634. 
10. Gajjar K, Martin-Hirsch PL, Martin FL. CYP1B1 and hormone-induced cancer. Cancer 
Lett. 2012;324(1):13-30. 
11. Patterson LH, Murray GI. Tumour cytochrome P450 and drug activation. Curr Pharm 
Des. 2002;8(15):1335-47. 
12. McFadyen MC, Murray GI. Cytochrome P450 1B1: a novel anticancer therapeutic target. 
Future Oncol. 2005;1(2):259-63. 
 
 89
13. Guengerich PF, Chun YJ, Kim D, Gillam EM, Shimada T. Cytochrome P450 1B1: a 
target for inhibition in anticarcinogenesis strategies. Mutat Res. 2003;523-524:173-82. 
14. Swanson HI, Njar VC, Yu Z, Castro DJ, Gonzalez FJ, Williams DE, et al. Targeting 
drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab 
Dispos. 2010;38(4):539-44. 
15. Spink DC, Eugster HP, Lincoln DW, 2nd, Schuetz JD, Schuetz EG, Johnson JA, et al. 17 
beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the 
activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from 
heterologous expression of the cDNA. Arch Biochem Biophys. 1992;293(2):342-8. 
16. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 beta-estradiol 
hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A. 
1996;93(18):9776-81. 
17. Richardson GS, Dickersin GR, Atkins L, MacLaughlin DT, Raam S, Merk LP, et al. 
KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial 
cancer. Gynecol Oncol. 1984;17(2):213-30. 
18. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, et al. 
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic 
fatty liver disease. Drug Metab Dispos. 2009;37(10):2087-94. 
19. Michaels S, Wang MZ. The revised human liver cytochrome P450 "Pie": absolute protein 
quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics. Drug 
Metab Dispos. 2014;42(8):1241-51. 
20. Wang MZ, Wu JQ, Dennison JB, Bridges AS, Hall SD, Kornbluth S, et al. A gel-free 
MS-based quantitative proteomic approach accurately measures cytochrome P450 protein 
concentrations in human liver microsomes. Proteomics. 2008;8(20):4186-96. 
21. Shi Z, Dragin N, Galvez-Peralta M, Jorge-Nebert LF, Miller ML, Wang B, et al. Organ-
specific roles of CYP1A1 during detoxication of dietary benzo[a]pyrene. Mol Pharmacol. 
2010;78(1):46-57. 
22. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, et al. Reverse 
transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 
families in 22 different human tissues. Pharmacogenet Genomics. 2007;17(9):731-42. 
23. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human 













Chapter V: Induction of CYP4F2 in HepaRG and Sandwich-Cultured Hepatocytes (SCH) 






TABLE OF CONTENTS 
5.1 Introduction………………………………..………………………………………………..93 
5.2 Materials and Methods.……………………..……………………..………………………..96 
5.2.1 Chemicals and Reagents………………………………………………………......96 
5.2.2 Cell Cultures…………………………………………………………..……….….96 
5.2.3 Lovastatin Induction………………………………………………………….…...96 
5.2.4 Reverse Transcription and Real-Time PCR………………………………………97 
5.2.5 Microsome Isolation and LC-MRM-Targeted Method for Protein 
Quantification…………………………………………………………………………...98 
5.2.6 Statistical Analysis……………..………………………………………………....99 
5.3 Results…………………………...…………………………………………………………100 
5.3.1 Induction of HepaRG cells by lovastatin………………………………………...100 




TABLE OF FIGURES 
Figure 18. Protein and mRNA expression of CYP4F2 and other targets in differentiated HepaGR 
cells following induction by lovastatin.……………………………...…………………………101 
 
 92







Warfarin is one of the most commonly administered anti-coagulant drugs (1, 2). In the United 
States, two million people take warfarin annually for the treatment of blood clots, stroke, 
myocardial infarction, and other diseases (2, 3). However, this drug is responsible for the second 
highest number of emergency room visits, behind insulin, because of its adverse effects, mainly 
the risk of a lethal hemorrhage (4). Among the ten thousand reported cases of warfarin-induced 
hemorrhages in the United States from 1993 to 2006, a thousand were fatal (5). Additionally, the 
narrow therapeutic window of this drug has considerable inter-patient variability. The most 
important factors influencing this are co-administered drugs (6)  and genetic polymorphisms  (7-
13).  
 
Warfarin is metabolized by multiple CYP enzymes in the human liver, including CYP2C9 (14), 
CYP3A4 and CYP1A2 (15, 16). Polymorphisms in CYP2C9 and VKORC1, a target of warfarin, 
account for up to 25% of warfarin dose variance (12, 17). Another 20-30% of the variability 
could be explained by pharmacokinetic or pharmacodynamic interactions between warfarin and 
other drugs (6). Approximately 144 drugs have been reported to interact with warfarin (18). 
However, after the consideration of all known factors influencing dose variance, only about half 
of the clinical cases have been accounted for (4, 7). The unknown underlying reasons for dose 
variance require additional investigation at the molecular level. 
 
Warfarin reduces the circulating blood level of vitamin K1 (VK1), which functions as a blood 
clotting factor. In 2009, McDonald et. al. discovered that CYP4F2 genetic polymorphisms 
underlie warfarin dose variance. They demonstrated that VK1 was metabolized almost 
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exclusively by this enzyme. A CYP4F2 mutant allele caused an approximate 25% reduction in 
enzymatic expression, leading to decreased VK1 depletion; therefore, CYP4F2 mutant carriers 
need additional warfarin to reach the same drug potency as wild-type carriers. (19) 
 
In 2007, Hsu et. al. provided the first evidence that CYP4F2 expression was induced by 
lovastatin (1μM), a drug used in the treatment of hypercholesterolemia, in both HepG2 (human 
liver carcinoma) cells and primary human hepatocytes (20). They found both CYP4F2 mRNA 
and protein expression levels were elevated following lovastatin treatment. We hypothesize that 
lovastatin may interact with warfarin through the induction of hepatic CYP4F2. Consequently, 
patients who take lovastatin may require a lower dose of warfarin in order to avoid warfarin’s 
dangerous adverse effects.  
 
This hypothesis could be tested in different in vitro hepatic cell models, including differentiated 
HepaRG (human hepatoma) cells and primary human hepatocytes. The post-oral maximum 
human plasma lovastatin level that occurred four hours after lovastatin administration (40 mg) 
was determined previously in our lab to be less than 100 nM (21); therefore, the lovastatin 
concentrations used in in vitro cell cultures to study induction should be around 100 nM. Subtle 
changes in CYP4F2 expression due to lovastatin may require a highly sensitive assay. Western 
blots do not have adequate sensitivity. In addition, there is no commercially available CYP4F2 
specific antibody; CYP4F2 and CYP4F3B share greater than 93% amino acid sequence identity. 
However, Michaels et. al. established a highly specific and sensitive LC-MRM-based targeted 
method for the absolute quantification of CYP4F2, which potentially could be applied to 




The goal of this chapter was to perform induction studies in differentiated HepaRG cells and 
primary human hepatocytes with lovastatin at various concentrations. CYP4F2 protein and 
mRNA expression were quantified by a UPLC-MRM-based targeted proteomic approach and 
RT-PCR, respectively. If obvious, or statistically significant, CYP4F2 induction were measured 
following treatment with clinically significant lovastatin concentrations (lower than 100 nM), the 
observation may support the hypothesis. If lovastatin does not induce CYP4F2, the hypothesis 




5.2 Materials and Methods 
5.2.1 Chemicals and Reagents. Lovastatin was purchased from U.S. Pharmacopeia (Rockville, 
MD). DMSO, ammonium bicarbonate, dithiothreitol, iodoacetamide, and D-glucose were 
purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human CYP3A4, CYP4F2 and 
CYP4F3B Supersomes, prepared from baculovirus-infected insect cells expressing human CYP 
enzymes, were obtained from Corning Gentest (Woburn, MA). Williams’s E medium (WME), 
TrypLETM Express, FBS, GlutaMaxTM, SYTO® 82 orange fluorescent nucleic acid stain, ROX 
reference dye, and TRIzol® reagent were from Life Technologies (Carlsbad, CA). GoTaq® G2 
Hot Start Colorless Master Mix was acquired from Promega (Madison, WI). A BCA protein 
assay kit was purchased from Pierce Biotechnology (Rockford, IL).  
5.2.2 Cell Cultures. HepaRG cells and additives for HepaRG Growth and Differentiation 
Mediums were purchased from Biopredic International (Overland Park, KS). Primary human 
hepatocytes and OptIncubate hepatocyte medium was provided by XenoTech, LLC. (Lenexa, 
KS). HepaRG cells were cultured in Growth medium (WME supplemented with GlutaMax and 
HepaRG Growth Medium Supplement) for 2 weeks, followed by 2 weeks of Differentiation 
medium (WME supplemented with GlutaMax and HepaRG Differentiation Medium 
Supplement). The medium was refreshed every other day. Primary human hepatocytes were 
isolated and plated by the vendor. The medium was changed daily. All cells were maintained at 
37°C in 5% CO2 and 95% humidity. Induction experiments were carried out less than 72 hours 
after plating in primary human hepatocytes.  
5.2.3 Lovastatin Induction. Lovastatin stocks were prepared with DMSO, aliquoted and stored 
at -20oC prior to use. Lovastatin stocks or DMSO (vehicle) were added to HepaRG 
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differentiation medium to give final concentrations of 0, 0.01, 0.1, 1 and 25 μM, or to 
OptIncubate hepatocyte medium to give 0, 0.1, 1 and 10 μM; vehicle concentrations were equal 
to or less than 0.1% (v/v). The experiment was initiated by replacing the culture medium with 
lovastatin- or vehicle-containing medium. Cells were harvested at 24 hours with TRIzol for 
mRNA isolation and at 48 hours for cell microsomal protein extraction.  
5.2.4 Reverse transcription and real-time PCR. Total RNA was isolated from HepaRG cells 
and primary human hepatocytes using TRIzol reagent according to the manufacturer’s protocol. 
RNA concentration and purity were determined using a Nanodrop® ND1000 spectrophotometer 
(Nanodrop Technologies, Wilmington, DE). One μg RNA was reverse transcribed to cDNA 
using a High Capacity cDNA Reverse Transcription kit. Following first strand cDNA synthesis, 
12.5 ng cDNA, primer mix (1uM final), water and homemade RT-PCR reagent were mixed to 
give a final volume of 25 μL. The homemade RT-PCR reagent recipe was kindly provided by 
Dr. Dongwei Hui in the Department of Pharmacology and Toxicology at the University of 
Kansas; briefly, SYTO® 82 orange fluorescent nucleic acid stain (10 μM) and ROX reference 
dye (5 nM) were mixed with GoTaq® G2 Hot Start Colorless Master Mix (2x). PCR 
amplification and real-time monitoring were performed with an Applied Biosystems 7500 Fast 
real-time PCR system to evaluate CYP3A4, CYP4F2, LDL-receptor, HMG-CoA reductase, and 
TATA-box binding protein (TBP; housekeeping gene) expression. The primer sequences used 
were: 5’- TTCCAACTCACAGGATGAAGTAAG -3’ (forward) and 5’- 
GGACACACAAGCTGGGAAGA -3’ (reverse) for HMC-CoA reductase; 5’- 
GATCCTGTTCATGGCTTCATGTA -3’ (forward) and 5’- GGCCAGCCTCTTTTCATCCT -3’ 
(reverse) for LDL-receptor; 5’- CTTCACAAACCGGAGGCCTTTTGGT -3’ (forward) and 5’- 
TCCTTGAGTTTTCCACTGGTGAAGG -3’ (reverse) for CYP3A4; 5’- 
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CCTGACAGAAGGATGTCCCAG-3’ (forward) and 5’- CCCCAAAACCAGTTCCGTCT -3’ 
(reverse) for CYP4F2; 5’- CATCTTCCCCGTCATCCGTTTT-3’ (forward) and 5’- 
TTTTGTCACAAGGGCACTGAGC -3’ (reverse) for CYP4F3B; 5’- 
ATCTTTGCAGTGACCCAGCA -3’ (forward) and 5’- GTAAGGTGGCAGGCTGTTGT -3’ 
(reverse) for TBP. Amplification was performed with an initial denaturation of 95°C for 10 min 
followed by 40 cycles of 95°C for 10 s and 60°C for 35 s. The comparative threshold method 
was used to calculate the relative amount of mRNA in a sample compared to other samples. 
5.2.5 Microsome isolation and LC-MRM-targeted method for protein quantification. 
Microsomes were prepared from HepaRG cells and primary human hepatocytes as reported 
previously (22), with minor modifications. Briefly, harvested cells were homogenized in a buffer 
(pH 7.4) containing 50 mM Tris-HCl, 1 mM EDTA, and protease inhibitor cocktail (Roche, 
Indianapolis, IN) with a Dounce homogenizer. After homogenization, the samples were 
centrifuged at 10,000 x g for 30 min. The supernatants were collected and centrifuged again at 
150,000 x g for 60 min. The resulting pellet was resuspended in a buffer (pH 7.4) containing 10 
mM potassium phosphate and 20% (w/v) sucrose. Microsomal protein concentrations were 
measured using a BCA assay. The microsomes were stored at -80oC. 
Targeted proteomic quantification of CYP3A4, CYP4F2 and CYP4F3B protein levels in 
microsomal fractions was performed as described previously for other CYP enzymes with minor 
modifications (23, 24). Briefly, protein samples (30 μg) were reduced in an ammonium 
bicarbonate buffer (pH 8.0; 50 mM final concentration) containing dithiothreitol (4 mM final 
concentration) and heated at 60°C for 60 min to denature the proteins. After cooling to room 
temperature, the samples (90 μl total volume) were alkylated with iodoacetamide (10 mM final 
concentration) for 20 min in the dark and then digested with 1 µg trypsin at 37°C for 4 h. 
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Recombinant human CYP3A4, CYP4F2, and CYP4F3B Supersomes of known concentrations 
were used to create calibration standards (ranged from 0.002 to 5 pmol/digestion). All reactions 
were carried out in Protein LoBind microcentrifuge tubes (Eppendorf, Hamburg, Germany) to 
minimize protein or peptide loss due to binding. Reactions were quenched with storage at -80°C. 
A mixture of stable isotope-labeled signature peptides (1 µl; Thermo Scientific, Ulm, Germany) 
were spiked into thawed samples as internal standards prior to loading onto the autosampler 
(6°C) for ultra-high pressure liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) 
analysis as described previously.(23, 24) 
5.2.6 Statistical analysis. All experiments were conducted in triplicate or quadruplicate, unless 
noted otherwise. Student’s t tests (two-tailed, unpaired) were used to compare pairs of 






5.3 Results  
5.3.1 Induction of HepaRG cells by lovastatin. HepaRG cells were grown in growth medium 
for a minimum of two weeks prior to switching to differentiation medium. Minor toxicity was 
observed upon the switch; many attached HepaRG cells detached. The number of suspended 
cells decreased with each medium change and by the end of the first week of differentiation, no 
suspended cells remained. At the end of the second week, a mixed population of two cell 
morphology types were observed: hepatocyte-like colonies surrounded by epithelium-like 
monolayers. These two morphologies are commonly observed in differentiated HepaRG cell 
cultures (25, 26).  
In our previous induction study, CYP4F2 mRNA expression and DB289 O-demethylation 
activity peaked around 24 hours and 48 hours following treatment with the highest lovastatin 
concentration, 25 μM, respectively (data not shown). Therefore, these time points were used for 
the current induction study. Our lab reported previously that the peak lovastatin plasma 
concentration occurred 4 hours after oral administration and was lower than 100 nM (personal 
communication; Dr. Michael Zhuo Wang, University of Kansas). Differentiated HepaRG cells 
were incubated with 0 (vehicle control), 10, 100 and 1000 nM lovastatin to mimic the plasma 
concentration. Lovastatin is a known inducer of HMG-CoA reductase, LDL-receptor, and 
CYP3A4; these genes were monitored as positive controls. No statistically significant inductions 
were observed in any of the positive control gene or CYP4F2 mRNA levels with 10 or 100 nM 
lovastatin (Figure 18). Small but significant CYP4F2, HMG-CoA and LDL-receptor mRNA 
increases were observed with 1 μM lovastatin; there was no change in CYP3A4. At 25 μM 
lovastatin, all mRNA expression levels were significantly increased, with CYP3A4 increased 
approximately 3.5-fold compared to vehicle control.  
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Protein expression of CYP3A4, CYP4F2, and CYP4F3B also were monitored (Figure 18). No 
statistically significant difference was observed for either enzyme at any lovastatin 
concentration. However, in general, CYP expression per mg of cell microsomes decreased with 
increasing lovastatin concentration.     
 
Figure 18. mRNA and protein expression of CYP4F2 and other targets in differentiated 
HepaRG cells following treated by lovastatin. HepaRG cells were grown in growth medium 
for two weeks, followed by differentiation medium for another two weeks prior to treatment. 
Lovastatin was administered at 0, 10, 100, 1000, and 25,000 nM. mRNA expression at 24 hour 
post-lovastatin addition was measured by RT-PCR. Protein expression at 48 hour post-treatment 





5.3.2 Induction of primary human hepatocytes by lovastatin. Primary human hepatocytes 
were plated fresh by the vendor and cultured for less than 48 hours prior to the start of the 
experiment. Since lovastatin concentrations lower than 1 μM did not change CYP4F2 expression 
in differentiated HepaRG cells, the concentrations used in primary human hepatocytes were 
adjusted to 0, 0.1, 1, and 10 μM. At 0.1 μM lovastatin, two positive control genes, LDL-receptor 
and HMG-CoA reductase, showed a significant induction of 3.2- and 6.0-fold compared to 
vehicle control, respectively (Figure 19). Even though CYP4F2 mRNA increased 1.6-fold, the 
change was not statistically significant. At 1 μM lovastatin, CYP4F2, LDL-receptor and HMG-
CoA were increased significantly, 1.8-, 4.9- and 7.4-fold, respectively. All positive control genes 
showed a significant increase at 10 μM lovastatin. CYP4F2 expression, surprisingly, stayed at 
the same level as the vehicle control.  
No significant differences were measured in CYP protein expression at any lovastatin 
concentration (Figure 19). Compared to vehicle control, mean expression decreased with the 
addition of lovastatin; however, the decrease was not statistically significant, nor did it follow a 




Figure 19. mRNA and protein expression in lovastatin treated primary human hepatocytes. 
Fresh primary human hepatocytes were treated with 0, 0.1, 1, and 10 μM lovastatin for 24 hours 
(mRNA) and 48 hours (protein). mRNA expression was measured by RT-PCR. Protein 



































































5.4 Discussion  
Primary human hepatocytes are the golden standard for induction studies; however, they are 
expensive, lack a regular supply, not amenable to long-term studies and demonstrate large inter-
individual variability. Hepatic cell lines are an inexpensive substitution. Two such surrogates that 
are used often are HepaRG and HepG2 cells. HepG2 cells grow quickly, but lack DME and drug 
transporter expression. HepaRG cells have been used in several recent studies (27-30). This cell 
line possesses the ability to differentiate. Following differentiation, DME, including CYPs 
(especially CYP3A4), and drug transporter expression levels are increased significantly (25, 31). 
In the current study, we compared absolute protein expression and the ability of lovastatin to 
induce target genes in differentiated HepaRG cells to primary human hepatocytes from a single 
donor. Our data showed comparable CYP3A4 expression in the two in vitro models; however, 
differentiated HepaRG cells were inferior in CYP4F2 and CYP4F3B expression. Also, HepaRG 
cells were less sensitive to induction by lovastatin; LDL-receptor (3.2-fold) and HMG-CoA 
reductase (6.0-fold) mRNA levels were increased significantly in primary human hepatocytes 
with 100 nM lovastatin treatment (Figure 19), while no significant increase was observed in 
HepaRG cells.  
The in vitro induction experiments were successful, as the expression of the positive control 
genes were increased quite obviously with various lovastatin concentrations. Despite this, a 
significant CYP4F2 increase was not observed until 1 μM of lovastatin in both HepaRG cells 
and primary human hepatocytes. This concentration is at least ten times higher than the highest 
lovastatin plasma concentration measured in our lab (21). Therefore, the minimum CYP4F2 
concentration needed in vitro for induction, 1uM lovastatin, is likely not attainable in vivo. Hsu 
et. al. first demonstrated that 1 μM lovastatin induced CYP4F2 mRNA and protein levels in 
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HepG2 and primary human hepatocytes (20). Increased CYP4F2 protein was not observed in the 
current study. However, our protein quantification varied greatly, most likely due to protein loss 
during mechanical cell homogenization and microsome preparation. The Dounce homogenizer 
used in the current study may cause reduced cellular protein levels due to adhesion. Microsome 
preparation by differential centrifugation is known to result in the loss of a significant amount of 
microsomal protein across the various steps (data not shown). These technical issues may be 
resolved by lysing the cells with different cell lysis techniques (e.g., detergent) and/or measuring 
whole cell instead of microsomal CYP4F2.  
Although this short-term experiment failed to support our hypothesis, there is no guarantee that 
long-term lovastatin users would not experience drug-drug interactions with warfarin. Current in 
vitro induction studies only last for 48 hours, whereas patients are on lovastatin for months or 
years. It is difficult to carry out long-term induction studies in in vitro models because of 
declining cell viability/health over time. Additional experiments are warranted before ruling out 
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DME expression has an important role in the determination of drug pharmacokinetics, 
pharmacodynamics, and toxicity (32-34). The quantification of DMEs in the microsomal portion 
of various human organs using MS-based targeted proteomics has become a common practice in 
the field of drug metabolism and disposition (35-37). Targeted proteomics on a liquid 
chromatography-multiple reaction monitoring (LC-MRM) platform is an accurate and specific 
protein quantification tool, and can be multiplexed (23, 24, 36-39). However, the cost and time 
for method development/validation rises linearly with an increase in the amount of protein(s) to 
be quantified (38, 40). In 2006, Silva et. al. discovered that the intensity of the top three ionizing 
peptides of a protein correlates directly to the protein concentration within complex biological 
matrices when the label-free data independent acquisition strategy (DIA;  MSE technique is the 
Waters version of DIA) of the quadrupole-time of flight (Q-TOF) MS platform is applied (41). 
Since then, label-free Q-TOF MSE-based protein quantification has been adopted in some 
studies, due to its low cost and greater multiplexing capabilities (hundreds of proteins can be 
quantified simultaneously) (42-46).  
Label-free MSE quantification can be hampered by many factors. First, the proteomic analysis 
tools, especially nano-UPLC systems, have very low tolerance to biological contaminants, such 
as phospholipids, nucleic acids or undigested proteins. As a result, extensive sample cleanup, 
such as polyacrylamide gel electrophoresis (PAGE), filter-assisted sample preparation (FASP) or 
immunocapture, must be performed prior to the introduction of biological samples. However, 
PAGE suffers from incomplete digestion and peptide adsorption to the gel (47-49). FASP is 
troubled by low digestion reproducibility and poor peptide recovery (50). Immunocapture allows 
a limited number of proteins to be analyzed, therefore quantification throughput suffers.  
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Besides the sample preparation/cleanup process, digested peptides are lost to adsorption to glass 
or plastic vials (51, 52). In addition, trap columns, which are used for nano-UPLC systems to 
guard, de-salt and speed-up sample run-time usually, were found to lose polar peptides during 
the trapping process due to the column having low retention and a shorter length compared to 
analytical columns and particle sizes being larger (53).    
Finally, work done by Harwood, Achour et. al., and Wegler et. al. (presented at a roundtable 
session at the 2015 AAPS annual meeting) revealed large inconsistencies between label-free 
MSE protein quantification and targeted proteomics for the quantification of DMEs in HLMs 
(54-56). However, little attempt was made in explaining these inconsistencies. Regardless of 
peptide loss and varying digestion efficiency, DIA searches have an intrinsic false discovery rate 
(FDR) for peptide identification and protein searching. We hypothesize that the peptide or 
protein false positive discoveries (FPDs) occurring during data processing by the Waters® 
ProteinLynx Global Server (PLGS) also contribute to the inconsistencies between the two 
quantification techniques.   
In the current work, we sought to address the challenges above, which trouble label-free MSE 
proteomic quantifications. A quantitative FASP (qFASP) protocol that offers reproducible tryptic 
digestion, close to complete recovery of digested peptides, and sample cleanliness in terms of 
phospholipid removal comparable to that of the original FASP, was developed. An albumin-
masking protocol was evaluated and adopted to prevent peptide adsorption to sample vials. A 
sample loading/direct injection scheme was utilized to ensure complete peptide recovery prior to 
MS analysis. Recombinant DMEs at various concentrations were digested and analyzed by label-
free MSE quantification to assess the impact of FPDs on the linearity of protein quantification. 
Finally, ten individual HLMs (iHLMs) were processed with the qFASP protocol and the 
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abundance of various DMEs quantified using a nano-UPLC-Q-TOF-based label-free MSE and 
UPLC-MRM targeted proteomics. The resulting correlations were examined to determine the 





6.2 Materials and Methods 
6.2.1 CHEMICALS, ENZYMES, AND LIVER TISSUES 
Optima-grade acetonitrile, water, formic acid, and acetic acid were obtained from Fisher 
Scientific (Pittsburgh, PA). Protein LoBind Tubes were acquired from Eppendorf (Hamburg, 
Germany). Certified screw top 250 uL polypropylene sample vials were from Agilent (Santa 
Clara, CA). Ammonium bicarbonate (ABC), dithiothreitol (DTT), and iodoacetamide (IAM) 
were purchased from Sigma-Aldrich (Saint Louis, MO). Recombinant human FMO1, FMO3, 
FMO5, CYP1A2, CYP3A4, CYP3A5, CYP2C9, CYP2C19, and CYP4F2 were obtained from 
Corning Gentest (Woburn, MA). Pooled HLM (XTreme 200) and nine individual adult donor 
HLM (Table 1) were purchased from XenoTech, LLC (Lenexa, KS). Synthetic 13C and 15N 
stable isotope-labeled crude signature peptides were acquired from Thermo Scientific. The 
synthetic peptides, used previously as internal standards for the absolute quantifications of CYPs, 
FMOs and drug transporters (23, 24, 38, 39), were used in the current study as reference peptides 
to assess peptide recovery in FASP, qFASP, digested sample storage, and nano-UPLC sample 
loading methods (Table 5). These peptides span a wide range of the HPLC index spectrum, 
therefore offering a good representation for the proteome digests. All synthetic peptide 
sequences were confirmed by MS/MS fragmentation analysis using a Waters Xevo TQ-S triple-
quadrupole MS (Milford, MA). Sequencing-grade modified trypsin was purchased from 
Promega (Madison, WI). Hi3 Ecoli Standard and MassPREP Enolase Digestion Standard were 
acquired from Waters (Milford, MA). Both standards were dissolved in 20% (v/v) ACN to give a 
final concentration of 1 μM, aliquoted in protein LoBind vials, and stored at -80oC.  
6.2.2 IN-SOLUTION DIGESTION 
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The in-solution digestion of HLMs and recombinant DMEs was performed as described 
previously (23, 24, 38). Stable isotope-labeled peptides that had been used for the absolute 
quantifications of CYPs, FMOs, and various drug transporters in previous studies were combined 
and served as internal standards in the current study  (Table 5) (23, 24, 38, 39).   
 
Table 5. Stable isotope-labeled peptides used in the current study.   
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6.2.3 ORIGINAL FASP DIGESTION & ASSESSMENTS 
The FASP protocol was performed as described by Wisniewski et. al. in 2009 (57), with minor 
modifications. Briefly, 30-60 ug of pooled HLM protein was denatured in a 100 mM Tris/HCl  
solution (pH 7.5) containing 0.4% (w/v) sodium dodecyl sulfate (SDS) and 100 mM DTT at 
95°C for 3 min. The denatured protein was washed twice with 200 uL of UA solution (8 M urea, 
0.1 M Tris-HCl; pH 8.5) on Microcon 10kD filters (Merck Millipore Ltd., Ireland) equilibrated 
with LC-MS grade water, and centrifuged at 14,000 x g for 40 min. The addition of 50 mM IAM 
in UA solution (100 uL) to the samples was followed by shaking at 600 RPM for 1 min, 
incubation in the dark for 20 min, and centrifugation at 14,000 x g for 30 min. A wash with UA 
solution (100 uL) was performed again, followed by two washes with 50 mM ABC (100 uL; 
14,000 x g for 30 min). Trypsin (a ratio of 1 ug trypsin: 30 ug sample), in 50 uL of 50 mM ABC, 
was added to the filters, and the samples shaken at 600 RPM for 1 min and incubated at 37°C for 
4 hours. Stable isotope-labeled reference peptides were spiked into the digest solutions. The 
filters then were put on top of a protein LoBind vial and centrifuged at 14,000 x g for 20 min. 
NaCl solution (0.5 M; 200 uL) was added to each filter, centrifuged, and combined with the first 
filtrate. Desalting of the filtrate was carried out on Pierce PepClean C-18 spin columns 
(Rockford, IL) according to the vendor’s protocol.  
Contributions of SDS and urea on the digestion of DMEs. FASP was performed as described 
above, with both SDS and urea, with SDS only, with urea only, or without either. In the SDS 
only digestion, UA solution was replaced by 20 mM ABC. In urea only samples, SDS was 
absent during the protein denaturation step. In 2012, Cunningham et. al. showed that a high NaCl 
concentration (1M) was basically ineffective in the recovery of digested peptides from cellulose 
made molecular weight cut-off (MWCO) filters (58). HLM tryptic digests were eluted by adding 
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100 uL of 50 mM ABC, centrifuged as above, and eluted again with two additional rounds of 50 
uL 50 mM ABC. The three eluents were combined and injected for UPLC-MRM peptide 
quantification.  
Recovery of digested peptides from MWCO filter. MWCO filters were equilibrated with LC-
MS grade water and positioned on top of protein LoBind tubes. Concentrated reference peptide 
stocks dissolved in 50 uL of 50 mM ABC were added to each filter (peptide elution groups) or 
directly to the LoBind tubes below the empty filter (“full recovery” control groups). The filters 
of each group were eluted with either four rounds of 100 uL of 50 mM ABC or four rounds of 
100 uL of 20% (v/v), 50% (v/v) or 60% (v/v) ACN and centrifugation at 14,000 x g for 30 min. 
Following the fourth elution, the centrifugation step was increased to 60 min. The eluents were 
collected in protein LoBind vials and subjected to UPLC-MRM analysis. Peptide recoveries in 
each elution condition were presented as the peptide peak area ratio between the “peptide elution 
groups” divided by the “full recovery control groups”.  
6.2.4 qFASP DIGESTION AND ASSESSMENTS 
The qFASP digestion protocol is detailed in 6.5 qFASP protocol. The protocol is compared to 
the well-established, in-solution digestion protocol for quantification of DMEs in pooled HLM. 
The removal of phospholipids is compared to the original FASP protocol.  
HLM digestion by qFASP vs. in-solution. Recombinant CYP3A4, CYP1A2, or FMO5 at 0, 1, 
2, and 4 pmole were spiked into 40 ug of pooled HLM (XTreme 200), and underwent both 
qFASP and in-solution digestion. Samples (4 uL) were subjected to UPLC-MRM for signature 
peptide quantification. The lower limits of quantification (LLOQ) of qFASP were evaluated by 
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processing a mixture of recombinant CYP1A2, CYP2C9, CYP3A4, CYP4F2 and FMO3, 
ranging from 1 fmole to 4000 fmole/digestion, and analysis by UPLC-MRM.  
Sample vial binding site masking & evaluation. Reference peptides dissolved in LC-MS grade 
H2O, 15% (v/v) ACN, or 50% (v/v) ACN were added to un-masked, certified polypropylene 
sample vials. To mask hot spots in the sample vials, 200 uL of 2mg/mL bovine serum albumin 
(Thermo Scientific, Rockford, IL) were added and the vials incubated overnight. The albumin 
was removed from the sample vials and stored for another masking later. The masked vials were 
rinsed twice with 200 uL LC-MS grade water by gently pipetting up and down. Reference 
peptides dissolved in water then were loaded into the masked vials for analysis. To examine 
potential signal interferences that may be introduced by remaining free albumin, nine 
consecutive injections of 10 uL of 20 mM ABC solution that was stored in albumin masked vials 
were analyzed by UPLC-MS scan. Chromatography and instrument settings were the same as in 
a previous report (38). MS scan was set so that the third quad of Waters XEVO TQ-S was 
scanning between 100-2000 m/z every two seconds while the collision energy remained at 4 eV 
throughout the LC run. The presence of free albumin also was checked with the Pierce BCA 
protein assay (Thermo Scientific). The sample loading volume was five times that suggested in 
the vendor’s protocol, in order to increase the BCA sensitivity.  
Evaluation of phospholipid remaining in qFASP vs. FASP digest. In-source fragmentation of 
phospholipids generate choline or phospho-choline ions, which can be monitored at 104 or 184 
m/z (59). Two sets of LC conditions were used to examine phospholipid content in the HLM 
digests. The first set was the same as the UPLC conditions for analysis of the digested peptides. 
The second set was run on an Agilent Zorbax Bonus-RP column (2.1 x 50 mm, 3.5 um) with a 
0.5 mL/min flow rate. Elution started at 20% (v/v) B for 1 min, followed by a 7 min gradient 
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linearly raised to 100% B, maintained for an additional min, and returned to 20% B. The two LC 
conditions shared the same mobile phase. The MS settings also were the same as those used for 
peptide monitoring, except that the cone voltage was set at 90 V to encourage in-source 
fragmentation. Both quad one and quad three were set at 104 or 184 m/z throughout the entire 
chromatographic run.  
6.2.5 UPLC-MRM AND NANO-UPLC MSE SETTINGS 
UPLC-MRM settings were the same as those reported previously. Parameters needed for the 
targeted quantification of stable isotope-labeled peptides and the corresponding signature 
peptides were published previously and summarized briefly in Table 5.  
The nano-UPLC systems used consisted of a Waters nano Acquity Binary Solvent Manager and 
nano Acquity Sample Manager. Mobile phases A and B were water and acetonitrile containing 
0.1% (v/v) formic acid, respectively. Table 6 contains details of the LC columns, sample 



























































Prior to data acquisition, the Waters Xevo-G2 Q-TOF was run for over a week with other 
samples in order to prime the detector, ensuring it is suitable for quantification analysis. The Q-
TOF detector was setup with the infusion of a leucine encephalin peptide and a mass calibration 
profile created using glu-fibrinopeptide. Sample eluent was introduced to the Q-TOF by a nano 
flow sprayer equipped with a Thermo stainless steel emitter (50 mm length, 360 um O.D.), 
which is glued to a 1 cm, 380 um I.D. silica capillary at the inlet end. The emitter position was 
fine tuned for optimal signal intensity. The Q-TOF was run under positive mode with a 2.8 kV 
capillary voltage, 30 V sampling cone voltage, 0.2 extraction cone, 100oC source temperature, 
350oC desolvation temperature, 50 L/H cone gas flow, 0.5 bar nano-flow gas pressure, and 800 
L/H desolvation gas flow; scanning occurred at 100-1800 m/z every second with a 0.014 s inter-
scan delay. Precursor ions were collected under 4 eV collision energy (CE), and the product ions 
produced with a 10-38 eV CE ramp.  
6.2.6 LABEL-FREE NANO UPLC MSE DATA QUALITY & IMPACT OF FPDs ON MSE 
PROTEIN QUANTIFICATION 
Equal amounts of recombinant CYP3A4, CYP3A5, CYP2C9, CYP2C19, FMO1, FMO3, and 
FMO5 were combined and processed following the in-solution digestion protocol with an 
increasing pmol of recombinant protein. The digests were subjected to nano UPLC-MSE 
analysis. Each digested recombinant protein was loaded onto the column at 1, 5, 10, or 40 fmole 
per loading.  
 
6.2.7 LABEL-FREE NANO-UPLC MSE  AND TARGETED UPLC-MRM 
QUANTIFICATION OF DMEs IN iHLMs 
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Digestions of 40 ug iHLMs were carried out according to the qFASP digestion protocol (6.5 
qFASP protocol). Prior to drying with the speedvac, peptides recovered from the MWCO filters 
with 60% (v/v) ACN were divided; one part was spiked with 2.5 pmole of Hi3 Ecoli Standard for 
label-free nano UPLC-Q-TOF MSE quantification, while the other part was spiked with stable 
isotope-labeled peptides for UPLC-MRM targeted quantification. The targeted quantification of 
iHLMs was calibrated using a mix of recombinant DMEs,CYP1A2, CYP2C9, CYP3A4, 
CYP4F2 and FMO3, each between 1 and 4000 fmole/qFASP digestion and processed in a 
manner similar to that of the iHLMs. An equivalent amount of HLM digest (1.28 ug; 5 uL) was 
injected onto the nanoUPLC column for each sample; 2.56 ug was loaded into the UPLC 
column. During MSE data collection, lock-spray mass calibration was not used due to a previous 
observation that sample-probe nano-spray was often disturbed during lock-spray collection. All 
post-data collection masses were calibrated manually through adjustment of the “calibration 
gain” by matching the recorded m/z of the doubly charged VIGQNEAVDAVSNAIR peptide 
(one of the six Hi3 standard peptides) to its theoretical doubly charged m/z of 828.4392.  
6.2.8 DATA ANALYSIS 
Both Xevo TQ-S triple quadrupole MS and Xevo G2 Q-TOF were operated under Masslynx 4.1 
(Waters, Milford, MA). Data analysis for targeted UPLC-MRM protein quantification has been 
reported previously (38). MSE data were analyzed by PLGS 2.5.1 with the following settings: 
lock mass, 785.8426 Da/e (not applied for the iHLM analysis); low and high energy threshold, 
250 counts and 100 counts; intensity threshold, 500 counts; 3 minimum peptide match required 
per protein; 3 minimum ions required per peptide; false positive rate (FDR), 1%; 
carbamidomethyl cysteine and oxidation methionine set as fixed and variable modifications; and 
1 tryptic missed cleavage. All spectrums were searched against the reviewed human proteome 
 
 124
FASTA databank that was downloaded from Uniprot.org (June-24-2015). Sequences of E. coli 
Chaperone protein ClpB (P63284) and S. cerevisiae enolase 1 (P00924) were added manually to 
the databank. PLGS output were analyzed further by Synatper (v 1.12.0), according to the 
author’s manual-script (60) and reference manual (http://lgatto.github.com/synapter/), for the 
calculations of nano UPLC retention time reproducibility, Q-TOF mass accuracies, number of 
significant peptides under 1% FDR, and PLGS score distribution for PLGS pass 1 and pass 2 
searches. All correlations and additional statistics were performed with GraphPad Prism 











6.3 Results and Discussion 
6.3.1 qFAPS DIGESTION OF HLM 
qFASP optimizations and assessments. The original FASP is known to have dramatic peptide 
loss as acknowledged by Wisniewski et. al. in 2009 (57). In addition, Hustof et. al. showed that 
FASP was unable to completely remove the added denaturant, SDS, and potential issues such as 
SDS co-eluting with the peptide(s) during LC-MS analysis may occur (61). Either of these two 
problems would affect label-free nano-UPLC analysis adversely. Therefore, it is vital to assess 
peptide loss in each step of the FASP protocol and the role of additives, like SDS and urea, in the 
digestion and analysis of DMEs. 
FASP were performed for the digestion of HLM with or without SDS or urea (Figure 20). 
Quantitative UPLC-MRM analysis of the digested signature peptides revealed that both SDS and 
urea caused large digestion variability, as demonstrated by the error bars (range) (Figure 1 A, B, 
C). Although each digestion group was performed in duplicate only, the large variability of the 
FASP protocol was consistent with previous reports. In 2014, An et. al. described a 14.1-29.6% 
CV when monoclonal antibodies were digested by FASP and quantified by targeted LC-MRM 
with stable isotope-labeled peptides as internal standards (62). In the current study, the 
variability was significantly smaller when SDS and urea were not present in the digestion (Figure 
1D). The low variability was confirmed by UPLC-MRM in all subsequent HLM digestions 
performed without either of the denaturants. The roles of SDS and urea were probed further by 
correlation of the mean of the duplicated peak areas from digested signature peptides in different 
digestion groups, using urea only, SDS only or neither, giving near unity slopes and a correlation 
coefficient close to 1 (Figure 21). These results suggested that the digestions of the signature 
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peptides in the targeted proteins, CYPs, FMOs, OATPs or OCT1, did not benefit from the 
addition of SDS or urea. 
 
Figure 21. Assessing SDS and urea in the digestion of DMEs in pooled HLM with the FASP 
protocol. FASP digestion of 30 ug of pooled HLM was performed with both SDS and urea (A), 
SDS only (B), urea only (C), or without either (D). Peptide peak areas were results of 
quantitative targeted UPLC-MRM analysis of the HLM digests. Duplicate digestions were 
performed in each group. Bars and error bars represent mean and range.   

























































































































































































































































































































































































































































































































































































































































































































   
Figure 22. Correlation of signature peptides digested by FASP performed with or without 
SDS or urea. Each data point is the mean peptide peak area from the targeted UPLC-MRM 
analysis of duplicate 30 ug HLM tryptic digestions.  
  
The original FASP protocol used 0.5 M NaCl for the recovery of digested peptides from the 10 
kDa MWCO filter and subsequently desalted with C18 solid-phase extractions for LC-MS 
analysis. Cuninngham et. al. showed that a high concentration of NaCl (1M) was basically 
ineffective in eluting digested peptides from the MWCO filters. We observed that a significant 
amount of peptides remained on the filter following the 5th or 6th filter elution with water or 50 
mM ABC (data not shown). These results indicate that aqueous or aqueous salt solutions will not 
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allow for full peptide recovery from the filters. In addition, high salt elution requires an extra 
downstream desalting step, which also causes peptide loss. Current experiments examined the 
use of 20, 50, or 60% (v/v) ACN for peptide recovery. Increased peptide recovery was observed 
with increased ACN concentration (Figure 23). An almost complete recovery of all hydrophilic 
(lower retention time) and hydrophobic (high retention time) reference peptides was achieved 
using four rounds of elution with 60% (v/v) ACN. In fact, three rounds of elution with 60% (v/v) 
ACN was found to give comparable recovery (data not shown); the fourth round was performed 
in the hope of recovering potential long chain, more hydrophobic peptides. Elution with 60% 
(v/v) ACN also eliminates the SPE desalting step. Assessments of the C18 desalting cartridges 
showed loss of hydrophilic peptides and increased variability (Supplemental Figure 1), and 




Figure 23. Recovering synthetic stable isotope-labeled reference peptides from YM-10 
Microcon filters. Synthetic peptides were recovered by elution with water or 20%, 50% or 60% 
(v/v) ACN (see Materials and Methods). Peptides were analyzed by UPLC-MRM and retention 
times were results of BEH C18 analytical column separation. Error bars represent standard 
deviations or ranges (20% ACN elution).  
  
Sample vial masking and validations. Peptides can easily bind to plastic or glass surfaces due 
to their amphipathic nature. Untreated polypropylene sample vials were used in the current 
study. Digested samples dissolved in water were found to experience major signal loss for 


































































































































































































hydrophobic peptides. When 2%, 5%, 10%, 15%, 20% or 50% (v/v) ACN were used to dissolve 
reference peptides, the hydrophobic peptide signal increased proportionally to the percentage of 
ACN (peptides in 0, 15, and 50% (v/v) ACN are shown in Figure 4 A and B). Hydrophobic 
peptide peak areas plateaued at 15% (v/v) can, whereas hydrophilic peptides were retained less 
and less on the BEH C18 column (2.1 mm I.D.) (Figure 24 B) during UPLC-MRM analysis. 
However, when peptides dissolved in 15% (v/v) ACN were loaded onto a Symmetry C18 nano 
trap column (180 um I.D.; intended for MSE analysis), many hydrophilic peptides suffered major 
signal loss. Although the use of ACN to dissolve the peptides solved the issue of peptide binding 
to polypropylene sample vials, it caused peptide loss at the nano-UPLC column due to pre-
elution. This dilemma indicates that all digested peptides should remain in an aqueous solution 
while not binding to polypropylene vials. In 1976, Felgner et. al. discovered that artificial 
hexokinase activity loss in polypropylene vials can be reversed by masking the vials with 
albumin, likely due to albumin competitively inhibiting the binding of enzyme to the vial (63). 
Therefore in the current study, sample vials were incubated with albumin (2 mg/mL) overnight 
and rinsed twice with water. Reference peptides dissolved in water and stored in albumin-
masked vials had almost the same UPLC-MRM peak area as that of the peptides dissolved in 
15% (v/v) ACN and stored in un-masked vials (Figure 24C). Concerns arising from vial-masking 
include the introduction of free albumin to the nano UPLC-Q-TOF system causing background 
interference in peptide analysis or increased back pressure in the nano column (75 um i.d.). Up to 
nine consecutive injections of water in albumin masked vials were analyzed by MS scans from 
UPLC-triple quadrupole or nano UPLC-Q-TOF. No identifiable albumin signal was observed in 
the background of any of the consecutive injections. Following the primary over-night coating, 
the vials were rinsed twice with water. Only sodium formate polymer or protonated formic acid 
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polymer signals were observed in the solvent front after the first vial wash. These interferences 
disappeared after the second wash.  
 
Figure 24. Preventing peptide adsorption to polypropylene sample vials. Synthetic isotope-
labeled peptides were dissolved in water or 15% or 50% (v/v) ACN, and stored in un-masked 
sample vials were compared to the same concentrations of peptides dissolved in water and stored 
in albumin masked vials. Peptides were measured by UPLC-MRM. Error bars represent standard 
deviations.  
  
Phospholipid remaining in qFASP vs. FASP digest. Phospholipid contamination from human 
tissue samples pose detrimental consequences in nano UPLC-Q-TOF label-free analysis, as it 
can cause large interferences in the current, carry over to many subsequent injections, inhibition 
of peptide signal due to its preferential ionization (64), and ion-pairing with nano column 
bedding, greatly reducing its separation efficiency and life time. As a result, a majority of 
phospholipids must be expelled from biological samples before the digests can enter the nano 
scale analytical column. Phospholipid removal is one key feature of qFASP, which was assessed 






































































































































































An in-source fragmentation method that measures fragmented phospholipid products of choline 
and phospho-choline, which have unique signature masses at 104 and 184, was used for the 
detection of phospholipids in HLM digestion samples.(59) HLM digestions prepared by different 
methods were injected on two columns using different elution gradients to provide additional 
confirmation (Figure 25). A mix of synthetic peptides was injected to both columns and served 
as the “no phospholipid” negative control. Injections of in-solution digested HLM were the 
positive control. Peaks present in the positive control chromatogram but not in the negative 
control indicate elution of phospholipids. On the BEH-C18 column (same column and gradient 
for targeted protein quantification) (Figure 25 A and B), qFASP digested HLM showed similar 
cleanliness as the negative control. On the Zorbax bonus-RP C18 column, qFASP reached 




Figure 5. Chromatograms of in-source fragmented phospholipid that remained in qFASP, 
FASP, or in-solution digested HLM solutions. The digestion products of 40 ug pooled HLM 
were eluted on a BEH C18 UPLC column (A, B) or a Zorbax Bonus RP column (C, D) with the 
elution gradient used for peptide analysis or polar lipid analysis. See detailed LC conditions in 
Materials and Methods.  
  
qFASP quantification limits and quantification coherence compared to in-solution 
digestion. In-solution digestion is a quick yet unclean process for absolute protein quantification 
on the LC-MRM platform, and has been well established and adopted widely (23, 24, 36-39). To 
Reten on Time (min) Reten on Time (min) 





determine whether qFASP maintains the quantitative nature of sample processing, a thorough 
comparison to in-solution digestion must be performed.  
The lower limit of quantification (LLOQ) was determined by the digestion of mixed recombinant 
CYP1A2, CYP2C9, CYP3A4, CYP4F2, and FMO3 at various concentrations (1-4000 fmole) by 
qFASP. Very sensitive quantifications were achieved with qFASP digestion (Table 2). The 
LLOQ of some peptides reached 1 fmole per digestion, CYP3A_PEP1_L and 
CYP1A2_PEP2_L. The detection limits of many signature peptides are comparable or superior 
to those obtained previously with in-solution digestion. Two peptides of CYP4F2 reached 
LLOQs of 5 fmole/digestion in qFASP, 10 times more sensitive than the 50 fmole/digestion 
LLOQ achieved with in-solution digestion (23). Two signature peptides of CYP3A4 also reached 
lower LLOQs, 2-20 times lower than those achieved with in-solution digestion (24). The 
improvement in quantification sensitivity may be due to reduced background noise or ionization 
inhibition resulting from the qFASP sample cleaning procedure, or reduction/elimination in 
peptide adhesion to sample vials due to albumin vial masking. At a minimum, this experiment 
demonstrated that qFASP was able to recover very small amounts of digested peptides with great 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Recombinant DMEs at different concentrations were spiked into pooled HLM to make artificial 
individual HLMs (AiHLMs). UPLC –MRM analysis of AiHLMs prepared by both qFASP and 
in-solution digestion revealed quantification similarities (Figure 26). Chromatographic peak 
areas of signature peptides digested from spiked in recombinant enzymes tracked closely 
between methods (Figure 26 A-G). Four replicates of all qFASP digestions showed excellent 
reproducibility (narrow error bars), which confirmed previous observations that removing SDS 
and urea increases digestion reproducibility (Figure 21D). The correlation of all recorded 
signature peptides from both methods showed a near unity slope and close to zero y-intercept at 
all ranges (Figure 26H). Signature peptides resulting from both digestion methods reach ratios 
close to one (Figure 26I). This again confirms that 60% (v/v) ACN recovers almost all peptides, 
whether they are hydrophilic or hydrophobic, from the MWCO membrane. Although the peptide 
peak area ratio in the hydrophilic region deviated more from one. This might be caused by 
insufficient evaporation of ACN in the qFASP procedure (30 min speed-vac). Later qFASP 
digestions were performed with a longer speed-vac time (1 hour but varied depending on the 
speed-vac system) for better chromatographic peak shape. Overall, these two experiments 
demonstrated that qFASP preserved the quantification nature of HLMs and achieved similar or 




Figure 26. Comparison of quantitative FASP (qFASP) to in-solution digestion of HLM. 
Recombinant CYP3A4, CYP1A2, and FMO5 of 0, 1, 2, and 4 pmoles were spiked into 40 ug 
pooled HLM to make artificial individual HLMs (AiHLMs). These AiHLMs were digested by 
both qFASP and in-solution digestion. The y-axis is the UPLC-MRM chromatographic peak area 
of the monitored signature peptides digested from AiHLMs. Error bars represent standard 
deviations.    
  
6.3.2 LAB-FREE DIA DATA QUALITY, FPD EVALUATION, AND NANO-UPLC 
OTIMIZATION  
NanoUPLC Q-TOF MSE data quality. Poor data quality leads to misidentification or even 
 CYP1A2_PEP2
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uninterpretable data for PLGS. Therefore, data quality should be checked first hand. Here, mixed 
recombinant DME proteins were subjected to in-solution digestion and analyzed by nanoUPLC-
Q-TOF MSE. Synapter (60) on R Script was used for data quality assessments. Figure 27A shows 
overlaid chromatograms of digestion mixtures of recombinant enzymes loaded onto a nano 
UPLC column from 1 to 40 fmole per species. Although online-trapping mode (Table 22, LC 
gradient B) was used for quick sample loading, good chromatographic reproducibility could still 
be seen in Figure 27A, and statistically confirmed (Figure 27B). Close to 100% of the m/z used 
by PLGS for significant peptide identification had an error less than 10 ppm mass error (Figure 
27 C and D); the same was seen with 1 and 5 fmole loading (data not shown). Additionally, the 
majority of significant peptide identification was within a 1% false positive rate, further 
confirmation of good mass accuracy in the data collection (Figure 28A). A comparison between 
searching the raw data against the human proteome to searching against the randomized decoy 
human proteome showed that very little recorded masses came from peptides of recombinant 
proteins (Figure 28 B and C). Most recorded masses (the large overlapped region on the lower 
PLGS scores on the x-axis) that poorly matches the regular human proteome may came from 
host insect cells, small-molecule contaminants in recombinant protein isolations, or sample 




Figure 27. Mixture of digested recombinant DMEs (CYPs & FMOs) were analyzed by DIA 
(MSE) proteomic strategies. A mixture of recombinant CYP2C9, CYP2C19, CYP3A4, 
CYP3A5, FMO1, FMO3, and FMO5 were serially diluted, digested, and analyzed by 
nanoUPLC-Q-TOF. Data were processed by PLGS and Synapter. The figure above shows 
stacked chromatograms (BPI) of digested enzymes at different concentrations (A); retention time 
differences between two separate injections with 10 and 40 fmole of each enzyme on the column 
(B); and mass accuracies in the two samples (C and D). The red solid line and blue shadow 
region in B represent mean and 95% confidence range of the difference in retention times.  
40 fmole of each species on column 
10 fmole on column 
5 fmole on column 
1 fmole on column 
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Figure 28. Cumulative plot of false discovery rate (FDR). Data generated by injection of 10 
fmole of each digested recombinant enzyme (CYP2C9, CYP2C19, CYP3A4, CYP3A5, FMO1, 
FMO3 and FMO5) on column (A). Dash line marks 1% FDR. Distribution of PLGS scores for 
pass 1 and pass 2 unmodified fully tryptic peptides. Blue, decoy peptides; purple, regular 
peptides (B and C).   
  
Impact of FPD on LFDI protein quantifications Many DMEs are homologs that share large 
portions of amino acid sequences. For example, CYP3A4 and CYP3A5 share 84% amino acid 
sequence identity; CYP4F2 and CYP4F3B have 93% sequence identity (24). Although a 1% 
false discovery rate (FDR) is applied to all data deconvolutions, it is still necessary to assess how 
falsely identified homologs might impact the quantification of true positive enzymes. Table 8 
shows the sum signal of the top three most intense peptides in each PLGS identified protein. The 
enzymes are not present in the digestion but “identified” by PLGS is considered false positive, 
which is denoted by red font (Table 8). As the on-column loading amount increased, more FPDs 
appeared with increasing “intensities”. Figure 29 shows the correlations of the top-three peptide 
intensities of quantified proteins and their loading amount. CYP2C9, CYP3A5, and FMO1, 3 
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CYP2C19, had curves bending downward. Surprisingly, when the intensities of the homologous 
FPDs were added back to the true positives (CYP2C18 and CYP2C8 added to CYP2C19; 
CYP3A43 and CYP3A7 added to CYP3A4), the linearity had a greater recovery. This data 
indicated that PLGS assigned intensities from true positive proteins to their highly similar false 
homologs. But only occasionally, the false intensity assignment would badly distort the true 
quantity (Figrue 29, CYP2C19).  
 
Table 8 . Signal intensities of PLGS identified proteins
  
 
Loading ^ CYP2C8* CYP2C9 CYP2C18* CYP2C19 CYP3A4 CYP3A5 CYP3A7* CYP3A43* FMO1 FMO3 FMO4* FMO5
1 fmoe 15395 29808 63745 57119 92772 141479
5 fmole 101066 2392 149709 118460 435684 3333 12419 237622 289122 68763
10 fmole 194750 8716 407653 277522.7 1117658 15067 4014 497965 592150 5793 159255
40 fmole 1559 819020 652035 684160 2802715 4933256 88852 61862 2512481 1910182 46143 645234
 CYP2C9, CYP2C19, CYP3A4, CYP3A5, FMO1, FMO3, and FMO5 were mixed in equal molar by the vendor provided norminal concentration;
^ amount of each protein loaded on to the column
* false positive dedused by PLGS




Figure 29. Impact of FPDs on protein quantifications using the “top three” rule applied by 
PLGS. The amount of enzyme digest loaded onto the column correlated with the intensity sum 
of the top three peptides calculated by PLGS. Red highlighted (*) enzymes were not present in 
the tryptic digestion, and therefore could be considered as FPDs. Red highlighted correlation 
coefficients and extrapolated dash lines are reconstitutions by adding the top three peptide 
intensities of the true positive enzymes to that of its FPD isoforms.  
Thus FPD might be an explanation for the inconsistencies between LFDI protein quantification 
and targeted proteomic quantification presented by Harwood, Achour et. al., and Wegler et. al. 
(54-56). 
NanoUPLC sample loading optimization. Peptide online trapping is typically used in nano 
UPLC separation for MSE proteomic analysis, taking advantage of its de-salting, analytical 
column-guarding, and fast sample loading (41, 42, 45, 60). The disadvantage of online trapping 
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peptides (Table I) where injected with online trapping mode, NTEA(I)K, FSDHAEEG(R), and 
FQENPEEG(R) were completely lost, while other hydrophilic peptides were reduced to a 
varying extent in the chromatogram (data not shown).  The same phenomenon was reported by 
the column manufacture as well (Waters Application Note 720005047EN).  
Loss of peptides undermines quantification by label-free methods. Table 2 gradient C describes 
an optimized direct injection approach that ensures no peptide is lost during nano UPLC sample 
loading. After 5 uL of sample was centered in the injection loop, around 2.5-times the loop 
volume (13uL) of 3% mobile phase B pushed the sample from the loop to the column head; the 
sample loop was switched off-line and the elution gradient started to separate the proteomic 
peptides. The trapping column was still in tandem connection to the analytical column without 
diverging to the waste (no trapping occurred). The trapping column only functions as a guard 
column. This loading method is slower than trapping, but fully reserves all tryptic peptides for 
nano analytical column separation. It was used in subsequent label-free MSE quantification of 
qFASP processed iHLM samples.  
6.3.3 CORRELATING LABEL-FREE NANO-UPLC MSE  TO TARGETED UPLC-MRM 
ON QUANTIFICATIONS OF DMEs IN qFASP PROCESSED iHLMs 
UPLC-MRM targeted quantification coherence of qFASP processed iHLMs. Ten iHLMs 
processed by qFASP were each divided into two parts, one spiked with stable isotope-labeled 
synthetic peptides for UPLC-MRM targeted quantification and the other part spiked with Hi3 E 
coli ClpB standards for LFDI nano UPLC-Q-TOF analysis. UPLC-MRM analyzed samples were 
calibrated with standard curves built by recombinant proteins processed in parallel with iHLMs.  
At least two signature peptides of each targeted protein were monitored by UPLC-MRM targeted 
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proteomics. The quantities of two signature peptides were correlated to examine quantification 
coherence. Almost all correlations revealed strong correlation coefficients, close to unity slope, 
and near zero y-intercept in all targeted proteins (Figure 30), indicating consistent quantification 
results between the different signature peptides. As a result, two signature peptide quantities 
were averaged for correlation to the label-free nano UPLC MSE measured results.  
 
Figure 30. Quantification coherence of UPLC-MRM targeted approach quantified CYPs 
and FMO3 in qFASP digested individual HLMs (iHLM) and pooled HLM. Quantities of 
two signature peptides from each protein were correlated. Equivalent of 2.67 ug HLM digests 
were loaded onto the UPLC column. CYP3A_PEP1_L (SLLSPTFTSGK) is shared by CYP3A4, 
CYP3A5 and CYP3A7 (B). CYP1A_PEP1_L (NPHLALSR) is shared by CYP1A1 and 
CYP1A2 (E).   
 Label-free nanoUPLC MSE quantification of iHLM and its correlation to targeted 
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approach. The lock-spray were found to interfere with sample signal stability, therefore it was 
turned off during analysis. Collected masses were manually calibrated according to the doubly 
charged M/Z of VIGQNEAVDAVSNAIR (one of the six Hi 3 standard peptides) 828.4392. Due 
to time constraints of the shared instrument, triplicate digests of 8 iHLMs were analyzed on the 
Q-TOF instrument. After 24 injections (each 150 min) of qFASP cleaned HLM samples onto the 
nano UPLC systems, no increase in column back-pressure, nor any raise of mass spectrum 
background noise, was observed, indicating a high level of sample cleanliness. 
PLGS was used for protein search and quantity calculation. For all injections, 241 proteins were 
resolved on average, with a minimum of 143 and a maximum of 305. An average (range) of 11 
(4—15) CYPs and 17 (14-18) UGTs were identified or quantified.  
Correlation between the two mass spectrometry based quantification methods revealed very 
strong correlations. CYP3A4 quantified by the two methods showed a R2=0.97 (Figure 31C); the 
sum of CYP3A4, 3A5, and 3A7 quantified by MSE correlated with CYP3A_PEP1 (peptide 
shared by the CYP3A4, 5, 7, quantified by UPLC-MRM) with a R2=0.97 (Figure 31D). 
Correlation of CYP4F2 showed the worst R2 of 0.73. MSE failed to identify CYP4F2 in one of 
the iHLM, therefore only 7 data points are shown in Figure 11 E and F. CYP1A2 was only 
quantified in 5 out of the 8 iHLMs analyzed by MSE, and not shown in the figure. Interestingly, 
FPD did not greatly bend any of the correlations in this study, unlike the measurement of 
recombinant CYP2C19 in Figure 9B. What’s more intriguing, is that the sum of CYP2C9 and 
2C8 quantified by MSE correlated well with CYP2C9 measured by the targeted MS method 
(Figure 31B), which may be explained by FPD as it could distort CYP2C8 quantification. 
However, studies showed that CYP2C9 and CYP2C8 are coherently expressed (35, 65) in human 
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CYP4F targetedly quantified by UPLC-MRM




























































































































Figure 11. Correlations between UPLC-MRM target quantification and nanoUPLC Q-
TOF DIA quantification of CYPs and FMO3. Forty microgram of each 9 individual HLM and 
1 pooled HLM were digested by qFASP. Equivalent of 2.67 ug and 1.28 ug HLM digests were 
loaded onto the UPLC and nanoUPLC columns respectively. CYP3A_PEP1_L 
(SLLSPTFTSGK) is shared by CYP3A4, CYP3A5, and CYP3A7 (D). CYP4F_PEP1_L 
(AEGGLWLR) is shared by CYP4F2, 4F3B, 4F12, and 4F11 (E). Enzyme quantity measured by 
UPLC-MRM shown on X-axis are average of two signature peptides of a protein, except 
CYP3A4, which only have one specific peptide monitored.  Due to limited Q-TOF instrument 
availability, only triplicated of 8 iHLMs were analyzed, thus 8 data points were correlated in the 
figures.  
 Worth to point out, MSE performed well in quantifying abundant species: CYP3A4, CYP2C9, 
and FMO3 are quantified in all injections; but lost certainty in quantifying less abundant species: 
CYP3A5 and FMO5 was quantified in 11 and 15 out of the 24 injections. These less abundant 
proteins would not be missed by targeted proteomic methods.  
Another discrepancy between MSE and targeted approach is that the MSE quantities are almost 
always higher than the quantity concluded by the targeted approach, as shown by the slopes in 
Figure 11 were all above one.  Our previous publications included experiments and discussions 
that dived great depth in explaining this issue (24, 66). Briefly, calibration standards used in 
UPLC-MRM targeted quantification are recombinant enzymes, whose nominal concentration 
was determined according to the prosthetic coenzyme group that only represents the amount of 
holoprotein in the solution. The nominal protein concentrations that defined calibrations 
standards are lower than the actual total protein (holoprotein + apoprotein) concentration. As a 
result, UPLC-MRM, which measures holoprotein, gave under-evaluated protein concentrations 
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compared to MSE, which measures total protein (holo+apoprotein).  
 As a conclusion, this study introduced qFASP protocol that allowed full recovery of highly 
cleaned digested peptides and eliminated/reduced peptide adhesion during sample storage. This 
new protocol enabled similar or superior detection sensitivity compared to in-solution digestion, 
while not sacrificing digestion efficiency. We demonstrated the impact of FPD on the 
quantification linearity when nanoUPLC Q-TOF based MSE was applied in quantifying highly 
similar protein homologs. A sample loading/direct injection method was optimized for 
nanoUPLC system to prevent peptide lost during online trapping process. Individual HLMs 
prepared by qFASP were quantified by both UPLC-MRM targeted approach and nanoUPLC-Q-
TOF based MSE methods. The two methods showed very strong correlations in many measured 
DMEs. We are the first to mitigate most of the problems that label free DIA technique have 
faced, and by applying the qFASP protocol, we observed very strong correlation between UPLC-
MRM targeted protein quantification and the Q-TOF based MSE approach. With the qFASP 
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6.5 qFASP protocol 
Quantitative Filter-assisted Sample Preparation (qFAS) Protocol for Label-free Data-
Independent Analysis (DIA) of Human Liver Microsome (HLM) or Recombinant DME Protein 
Using NanoUPLC-Q-TOF 
1. Reagents 
a. Millipore Microcon YM-10 10K MWCO centrifugal filters 
b. Denaturation buffer (DB): 40 mM ammonium bicarbonate (ABC),  10 Mm DTT 
c. Washing buffer A (WBA): same as DB 
d. Alkylation buffer (AB): 50 mM IAA in 40 mM ABC 
e. Washing buffer B (WBB): 40 mM ABC 
f. Trypsin Digestion buffer (TDB): keep trypsin to protein ratio between 1:30-1:50, 
20 mM ABC 
g. HLM: Xenotech, Pool of 200, 20 mg/mL 
h. Certified screw top 250 uL polypropylene sample from Agilent 
i. 2 mg/mL albumin acquired from Thermo Scientific 
j. Protein LoBind Tubes from eppendorf  
2. Procedure 
a. Add 200 uL water to Microcon filters, centrifuge 14000xg for 20 min for filter 
rinse and equilibration.  
b. Add 30-60 ug of HLM to 90 uL DB, heating up at 95 degrees for 3 min in protein 
Lobind vials 
c. Transfer denatured protein solution to Microcon filter. Keeping the transferring 
pipette tips. Wash the Lobind vials with 100 uL WBA and transfer the wash with 
the kept pipette tips to Microcon filters. 
d. Shake the filters at 800 RPM for 1 min, centrifuge 14000xg for 20 min, discard 
the flow-through 
e. Add 200 uL WBA to filters, centrifuge 14000xg for 20 min, discard the flow-
through, repeat this step and centrifuge for 30 min 
f. Add 100 uL AB, shake the filter at 800 RPM for 1 min, and incubate in dark for 
20 min. Centrifuge 14000xg for 20 min. 
g. Add 150 uL WBB to filters, centrifuge 14000xg for 20 min, discard the flow-
through, repeat this step and centrifuge for 30-40 min until very little liquid 
remains on the filter 
h. Add 50 uL TDB to filter, shake 800 RPM for 1 min. Use parafilm to seal the cap 
and the bottom of the filter. Incubate in 37 degree for 4 hours.  
i. Discard the parafilm, add 75 uL of acetonitrile (ACN) to the filter, shake at 800 
RPM for 1 min, centrifuge 14000xg for 20 min 
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j. Add 100 uL of 60% ACN, shake at 800 RPM for 1 min, centrifuge 14000xg for 
20-30 min. Repeat this step 
k. Add 100 uL of 60% ACN, shake at 800 RPM for 1 min, centrifuge 14000xg for 
40-60 min to dry the filter membrane. 
l. Collect all the eluent and transfer to protein LoBind vials, speed-vac to evaporate 
ACN and getting a desired volume. Note: Before speed-vac, thoroughly mix 
eluted peptide by vortex. Un-uniformly mixed peptide solutions may yield 
different remaining volume in intra-replicate samples after speed-vac. High 
remaining ACN jeopardies LC separation.   
3. Masking sample vials 
a. Add 200 uL 2 mg/mL albumin to Agilent polypropylene sample vials. Make sure 
no air bubbles in albumin solution. Store in 4 degree for more than 24 h. Discard 
the albumin or store for another masking. Add 200 uL water, gently pipeppet 
up/down 3 times. Repeat the rinse again. Do not touch the wall of the vial. 
Discard the wash.  
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7.1 General Conclusions 
LC-MRM-based protein quantification offers unparalleled specificity, versatility, accuracy, 
reproducibility and ease of method development. Our efforts in the development and validation 
of a method for the absolute quantification of CYP2C9, CYP2C19, FMO1, FMO3 and FMO5 
were successful. Good quantification linearity and reproducibility, as well as strong correlations 
to enzyme activity, were achieved. However, discrepancies between the use of recombinant 
protein and purified synthetic signature peptide for standards were identified. We concluded that 
recombinant protein is best for standards used in absolute protein quantification. As a result, we 
are calling for additional protein standards to become commercially available, thus supporting an 
increase in the quality of absolute protein quantifications. 
Using established and existing UPLC-MRM targeted protein quantification methods, the 
previously reported ontogenies of CYP3A4, CYP3A5, CYP3A7, CYP2C9, FMO1 and FMO3, 
determined by Western blot and enzyme activity assays, were confirmed. In addition, the 
multiplexing capability of LC-MS allowed the simultaneous characterization of CYP4F2, 
CYP4F3B and FMO5 ontogeny. CYP4F2 is expressed very low during the neonatal stage, but 
increased with age. CYP4F3B and FMO5 expression did not change with age. 
To screen CYP1B1-dependent anticancer prodrugs, a cell model, specifically KLE cells, must be 
characterized for the presence and expression level of CYP1B1. The characterization of this cell 
line using an enzyme activity assay was unsuccessful, due in part to low CYP1B1 activity; the 
only option remaining for characterization was CYP1B1 targeted proteomics. Utilizing 
microsomes isolated from different human tissues, the specificity of the targeted assay was 
confirmed. With this technique, KLE cells were shown to express CYP1B1 only, not CYPs 1A1 
or 1A2, which is required for the first stage of screening.  
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UPLC-MRM targeted proteomic quantification also was used for the mechanistic elucidation of 
potential drug-drug interactions. We hypothesized that CYP4F2 induction by lovastatin might 
potentiate warfarin’s therapeutic effect. To test this hypothesis, the induction of CYP4F2 by 
clinically significant lovastatin concentrations was examined in hepatic in vitro models. 
Although our induction studies were successful in both HepaRG and primary human 
hepatocytes, CYP4F2 increases could not be measured conclusively by UPLC-MRM or RT-
PCR, thus the hypothesis remains unanswered.  
An emerging Q-TOF-based label-free DIA approach for protein quantification is able to quantify 
hundreds of proteins at minimum cost, but with some problems. We developed the qFASP 
technique, allowing near complete recovery of cleaned, digested sample peptides. In addition, 
false positive discoveries in DIA were demonstrated to contribute to quantification distortion. 
We are the first to address a majority of the problems facing the label-free DIA technique, and by 
applying the qFASP protocol, we observed a very strong correlation between UPLC-MRM 
targeted protein quantification and the Q-TOF-based DIA approach.  
7.2 Future Directions of Mass Spectrometry-Based DME Quantification 
The adoption of qFASP sample preparation and analytical vial passivation, and the application of 
direct injection for nano-UPLC sample loading allowed the near full-recovery of clean proteomic 
digests. These improvements also drove the strong quantification coherence observed between 
the well-established UPLC-MRM targeted approach and the nano-UPLC-Q-TOF-based MSE 
analysis. However, nano-UPLC-Q-TOF analysis still had intrinsic limitations, such as losing 
detection/quantification sensitivity for DMEs of low abundance (e.g., CYP3A5 and CYP4A11), 
and occasional occurrences of quantity misassignment due to FPDs. These limitations are 
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fundamental instrument limitations and can be overcome by implementing better LC separation 
and mass resolution. In 2015, C. E. Doneanu et. al. reported the use of 2-dimensional (2D) nano-
LC with an ion-mobility Q-TOF MSE for the detection of host cell impurities (HCIs) in purified 
monoclonal antibodies at the 1 ppm level (1). PLGS also was used for the identification and 
quantification of HCI abundance. That same year, S. T. Mindaye et. al. also described the 
identification and relative quantification of over 2500 human bone marrow proteins with 
triplicate runs using 2D-nanoLC ion-mobility Q-TOF-based MSE analysis(2). Improved 
separation of masses in space (ion-mobility) and time (2D-nano LC) enabled greater detection 
sensitivity and higher protein identification confidence. These same improvements are 
anticipated should 2D-nano LC and ion mobility Q-TOF be used for the quantification of DMEs.  
Despite the excellent separation of mass achieved with 2D-LC ion mobility Q-TOF, this 
technique requires a great deal of training to master and effort to maintain, as well as 4-12 hours 
to process a single sample. It also yields enormous data files. An alternative high-throughput MS 
technique is QconCAT. In 2014, T. S. Batth et. al. performed targeted absolute quantification of 
over 400 E. coli proteins with a 5.5 min LC gradient (10 min total) using a QconCAT protein 
containing over 800 tryptic peptides (3). Since a majority of human DMEs have been identified, 
a single large QconCAT protein containing tryptic peptides for all the known DMEs could be 
constructed for global quantification of these enzymes.  
A second application for qFASP would be MS-based quantification of human drug transporters 
(DTs). Previous sample preparation methods for the digestion of DTs used detergents for protein 
solubilization; however, many of these methods were unable to remove the detergents prior to 
analysis. Although SDS and urea were not used for the sake of quantification reproducibility in 
the qFASP method, other detergents (e.g. sodium deoxycholate) could be examined to enhance 
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the digestion of DTs and possibly preserve reproducibility simultaneously. The downstream 
process of qFASP would still help to remove the detergent and preserve the quantitative nature 
of the digested samples.  
Overall, quantitative profiling of the human hepatic proteome using qFASP nanoUPLC-Q-TOF 
MSE could help further characterize new DME ontogeny patterns, discover new biomarkers for 
liver diseases, and profile DME induction patterns under the influence of new drugs and different 
disease states. In addition, this method to clean up protein samples while maintaining near total 
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Appendix I: Quantification of Flavin-containing Monooxygenases 1, 3 and 5 in Human 
Liver Microsomes by UPLC-MRM-based Targeted Quantitative Proteomics and Its 





Flavin-containing monooxygenases (FMOs) have a significant role in the metabolism of small 
molecule pharmaceuticals. Among the five human FMOs, FMO1, FMO3 and FMO5 are the 
most relevant to hepatic drug metabolism. Although age-dependent hepatic protein expression, 
based on immunoquantification, has been reported previously for FMO1 and FMO3, there is 
very little information on hepatic FMO5 protein expression. To overcome the limitations of 
immunoquantification, a UPLC-MRM-based targeted quantitative proteomic method was 
developed and optimized for the quantification of FMO1, FMO3 and FMO5 in human liver 
microsomes (HLM). A post-in silico product ion screening process was incorporated to verify 
LC-MRM detection of potential signature peptides prior to their synthesis. The developed 
method was validated by correlating marker substrate activity and protein expression in a panel 
of adult individual donor HLM (age 39-67 years). The mean (range) protein expression of FMO3 
and FMO5 was 46 (26 – 65) pmol/mg HLM protein and 27 (11.5 – 49) pmol/mg HLM protein, 
respectively. To demonstrate quantification of FMO1, a panel of fetal individual donor HLM 
(gestational age 14-20 weeks) was analyzed. The mean (range) FMO1 protein expression was 
7.0 (4.9 – 9.7) pmol/mg HLM protein. Furthermore, the ontogenetic protein expression of FMO5 
was evaluated in fetal, pediatric and adult HLM. The quantification of FMO proteins also was 
compared using two different calibration standards, recombinant proteins vs. synthetic signature 
peptides, to assess the ratio between holoprotein vs. total protein. In conclusion, a UPLC-MRM-
based targeted quantitative proteomic method has been developed for the quantification of FMO 
enzymes in HLM.  
For complete publication see: 
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Monooxygenases 1, 3, and 5 in Human Liver Microsomes by UPLC-MRM-Based Targeted 
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Significant age-dependent differences in pharmacokinetic (PK) parameters exist for 
metabolically cleared medications. Therefore, it is essential to obtain data on gene and protein 
expression of drug metabolizing enzymes (DMEs), as well as their catalytic activities in fetal, 
pediatric, and adult hepatic tissues for the development of mechanistic models. Although the 
relative expression of the cytochrome P450 (CYP) 3A, CYP2C and flavin-containing 
monooxygenases (FMO) enzymes have been previously published, this is the first study in which 
quantitative gene and protein expression of these DMEs were correlated with their corresponding 
functional activities in the same samples from target populations. Both the CYP3A and FMO 
families showed a distinct switch from fetal isoforms (CYP3A7, FMO1) to adult isoforms 
(CYP3A4, FMO3) at birth, while the CYP2C9 enzyme showed a linear maturation from birth 
into adulthood. In contrast, CYP2C19 expression was higher in pediatric samples compared to 
fetal and adult samples. Functional activity of the CYP2C family was linearly correlated with 
enzyme protein expression in pediatric and adult tissues, while the catalytic efficiency of 
CYP2C19 was greater in pediatric hepatic tissues compared to adult tissues; this is a surprising 
finding and suggests that cytochrome P450 enzymes may encounter a different micro 
environment in children versus adults. These data are critical to understanding the mechanistic 
basis underlying the faster clearance of certain medications in children versus adults, and can be 
incorporated into mechanistic models to enhance the accuracy of pediatric PK predictions. 
 
For complete publication see: 
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Cytochrome P450 1B1 (CYP1B1) is an anticancer therapeutic target due to its overexpression in 
a number of steroid hormone-related cancers. One anticancer drug discovery strategy is to 
develop prodrugs specifically activated by CYP1B1 in malignant tissues to cytotoxic 
metabolites. Here, we aimed to develop an in vitro screening model for CYP1B1-targeted 
anticancer prodrugs using the KLE human endometrial carcinoma cell line. KLE cells 
demonstrated superior stability of CYP1B1 expression relative to transiently transfected cells 
and did not express any appreciable amount of cognate CYP1A1 or CYP1A2, which would have 
compromised the specificity of the screening assay. The effect of two CYP1B1-targeted probe 
prodrugs on KLE cells was evaluated in the absence and presence of a CYP1B1 inhibitor to 
chemically “knockout” CYP1B1 activity (CYP1B1-inhibited). Both probe prodrugs were more 
toxic to KLE cells than to CYP1B1-inhibited KLE cells and significantly induced G0/G1 arrest 
and decreased S phase in KLE cells. They also exhibited pro-apoptotic effects in KLE cells, 
which were attenuated in CYP1B1-inhibited KLE cells. In summary, a KLE cell-based model 
has been characterized to be suitable for identifying CYP1B1-targeted anticancer prodrugs and 
should be further developed and employed for screening chemical libraries. 
 
For complete publication see: 
Wang, Z., Chen, Y., Wang, M. Z. Development of an in vitro model to screen CYP1B1-targeted 










Appendix IV: Quantitative FASP (qFASP) Offers Nearly Full Digest Recovery and Good 
Quantification Correlation between Targeted UPLC-MRM and NanoUPLC-Q-TOF-Based 





Quantification of human liver DMEs using LC-MRM targeted proteomic techniques has been 
well established. The high specificity and multiplexing of targeted proteomics comes at a price—
cost of synthetic signature peptides increase linearly with the amount of targeted proteins, and 
lengthy efforts for method establishment. In comparison, label-free data independent (LFDI) MS 
allows quantification of hundreds of proteins simultaneously for a negligible cost. However, this 
quantification technique suffers from a lack of quantitative protein clean up, sample storage, and 
chromatography methods that offer high reproducibility and full recovery of all digested 
peptides. Secondly, previous parallel studies comparing LFDI quantification with targeted 
proteomics yielded puzzling inconsistencies, indicating deeper flaws in data independent 
analysis (DIA), other than non-quantitative sample preparation methods that affected 
quantification accuracy. This study strives to answer both challenges that jeopardize the 
performance of LFDI quantification. Firstly, based on a recently introduced filter-assisted sample 
preparation (FASP) protocol, which is known to have severe peptide lost problem, a quantitative 
FASP (qFASP) protocol was established. By removing detergent and denaturing-salt at 
digestion, eluting peptides with 60% ACN on the filter, and storing peptides in albumin masked 
vials, qFASP achieved almost full peptide recovery, ensured similar DME digestion efficiency, 
and same or better level of sample cleanness compared to the original FASP protocol.  Secondly, 
a nanoUPLC sample loading and direct injection scheme was applied, which guaranteed no 
hydrophilic peptide loose, contrasting to previous online trapping method. Thirdly, false positive 
discoveries (FPD) occurred at LFDI quantification of homologous DMEs was evaluated on its 
impact on the linearity of protein quantification, which maybe another cause for the 
inconsistencies between LFDI and targeted proteomics. At last, 10 iHLMs were digested by 
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qFASP, DMEs quantified by targeted UPLC-MRM method were correlated with corresponding 
species quantified by nanoUPLC Q-TOF LFDI analysis. Despite FPD, good correlation 
coefficients (R2) between targeted UPLC-MRM proteomic method and nanoUPLC-Q-TOF-
based label-free protein quantification were observed (R2=0.97 for CYP3A4; R2=0.86 for 
FMO3; R2=0.85 for CYP2C9, etc.).  
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